NATIONAL INSTITUTES OF HEALTH NATIONAL INSTITUTE ON AGING INTRAMURAL RESEARCH PROGRAM



Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS)

Wave 7 Protocol

Principal Investigator Michele K. Evans, MD

Lead Associate Investigator Alan B. Zonderman, PhD

National Institute on Aging Laboratory of Epidemiology & Population Sciences Health Disparities Research Section NIH Biomedical Research Center 251 Bayview Boulevard Baltimore, MD 21224

NIH/NIA Protocol Number 09-AG-N248 Version No: 17.2 11/04/2022

| 1.0.0 Statement of Compliance 3 2.0.0 List of Abbreviations 4 3.0.0 Protocol Summary 5 4.0.0 Précis 6 5.0.0 Background and Scientific Rationale 7 6.0.0 Study Objectives 8 6.1.0 Ancillary studies, sub-studies and <i>pSITEs</i> 19 6.1.1 Neuroimaging Sub-study Objectives 20 6.1.2 Predictors of Personality Sub-study Objectives 20 6.1.3 Pennsylvania State University <i>pSITE</i> Roles and Responsibilities 7 7.0.0 Expected Risks and Benefits 21 8.0.0 Eligibility 22 9.0.0 Subject Enrollment 22 9.0.0 Subject Enrollment 22 10.0 Procedure Description 27 12.0.0 Collection and Storing of Human Sample Specimens and Data 32 13.0.0 Data Collection and Management Procedures 33 14.0.0 Quality Control 34 16.0.0 Regulatory Requirements 35 16.1.0 Informed Consent 35 16.2.0 Compensation 36 16.3.0 Subject Confidentiality 38 17.1.1 Poorly controlled hypertension and related medical non-compliance | Table of Contents | |
|--|---|----|
| 3.0.0 Protocol Summary 5 4.0.0 Précis 6 5.0.0 Background and Scientific Rationale 7 6.0.0 Study Objectives 8 6.1.0 Ancillary studies, sub-studies and <i>pSITEs</i> 19 6.1.1 Neuroimaging Sub-study Objectives (HANDLS Scan) 19 6.1.2 Predictors of Personality Sub-study Objectives 20 6.1.3 Pennsylvania State University <i>pSITE</i> Roles and Responsibilities 21 8.0.0 Eligibility 22 22 9.0.0 Subject Enrollment 22 9.0.0 Study Design and Procedures 23 11.0.0 Procedure Description 27 12.0.0 Collection and Storing of Human Sample Specimens and Data 32 13.0.0 Data Collection and Management Procedures 33 14.0.0 Quality Control 34 16.0.0 Regulatory Requirements 35 16.1.0 Informed Consent 35 16.1.0 Informed Consent 36 15.3.0 Subject Confidentiality 37 17.0.0 Participant Safety, Adverse Events & Problem Reporting 38 17.1.1 Poorly controlled dispeters mellitus and related medical non-compliance 39 17.1.2 Poorly controlled dispeters melitu | 1.0.0 Statement of Compliance | 3 |
| 4.0.0 Précis 6 5.0.0 Background and Scientific Rationale. 7 6.0.0 Study Objectives 7 6.1.0 Ancillary studies, sub-studies and <i>pSITEs</i> . 19 6.1.1 Neuroimaging Sub-study Objectives (HANDLS Scan) 19 6.1.2 Predictors of Personality Sub-study Objectives. 20 6.1.3 Pennsylvania State University <i>pSITE</i> Roles and Responsibilities. 21 7.0.0 Expected Risks and Benefits 22 9.0.0 Subject Enrollment. 22 9.0.0 Subject Enrollment. 22 10.0.0 Study Design and Procedures 23 11.0.0 Procedure Description 27 12.0.0 Collection and Storing of Human Sample Specimens and Data 32 13.0.0 Data Collection and Management Procedures 33 14.0.0 Quality Control 34 15.0.0 Statistical Considerations 34 16.0.0 Regulatory Requirements 35 16.1.0 Informed Consider 37 17.0.0 Participant Safety & Intent to Treat 38 17.1.1 Poorly controlled hypertension and related medical non-compliance 39 17.1.2 Poorly controlled diabetes mellitus and related medical non-compliance 39 17.1.3 Poorly controlled abathma/chronic obs | 2.0.0 List of Abbreviations | 4 |
| 4.0.0 Précis 6 5.0.0 Background and Scientific Rationale. 7 6.0.0 Study Objectives 7 6.1.0 Ancillary studies, sub-studies and <i>pSITEs</i> . 19 6.1.1 Neuroimaging Sub-study Objectives (HANDLS Scan) 19 6.1.2 Predictors of Personality Sub-study Objectives. 20 6.1.3 Pennsylvania State University <i>pSITE</i> Roles and Responsibilities. 21 7.0.0 Expected Risks and Benefits 22 9.0.0 Subject Enrollment. 22 9.0.0 Subject Enrollment. 22 10.0.0 Study Design and Procedures 23 11.0.0 Procedure Description 27 12.0.0 Collection and Storing of Human Sample Specimens and Data 32 13.0.0 Data Collection and Management Procedures 33 14.0.0 Quality Control 34 15.0.0 Statistical Considerations 34 16.0.0 Regulatory Requirements 35 16.1.0 Informed Consider 37 17.0.0 Participant Safety & Intent to Treat 38 17.1.1 Poorly controlled hypertension and related medical non-compliance 39 17.1.2 Poorly controlled diabetes mellitus and related medical non-compliance 39 17.1.3 Poorly controlled abathma/chronic obs | 3.0.0 Protocol Summary | 5 |
| 5.0.0 Background and Scientific Rationale. 7 6.0.0 Study Objectives 8 6.1.0 Ancillary studies, sub-studies and <i>pSITEs</i> . 19 6.1.1 Neuroimaging Sub-study Objectives (HANDLS Scan) 19 6.1.2 Predictors of Personality Sub-study Objectives 20 6.1.3 Pennsylvania State University <i>pSITE</i> Roles and Responsibilities. 20 6.1.3 Pennsylvania State University <i>pSITE</i> Roles and Responsibilities. 21 8.0.0 Eligibility. 22 9.0.0 Subject Enrollment. 22 9.0.0 Study Design and Procedures 23 11.0.0 Procedure Description 27 12.0.0 Collection and Storing of Human Sample Specimens and Data 32 13.0.0 Data Collection and Management Procedures 33 14.0.0 Quality Control 34 15.0.0 Statistical Considerations 34 16.0.0 Regulatory Requirements 35 16.2.0 Compensation 36 16.3.0 Subject Confidentiality. 37 17.1.0 Participant Safety, Adverse Events & Problem Reporting 38 17.1.1 Poorly controlled diabetes mellitus and related medical non-compliance. 38 17.1.2 Poorly controlled diabetes mellitus and related medical non-compliance. 39 | | |
| 6.0.0 Study Objectives 8 6.1.0 Ancillary studies, sub-study Objectives (HANDLS Scan) 19 6.1.1 Neuroimaging Sub-study Objectives (HANDLS Scan) 19 6.1.2 Predictors of Personality Sub-study Objectives 20 6.1.3 Pennsylvania State University <i>pSITE</i> Roles and Responsibilities 21 8.0.0 Eligibility 22 9.0.0 Subject Enrollment 22 9.0.0 Study Design and Procedures 23 11.0.0 Procedure Description 27 12.0.0 Collection and Storing of Human Sample Specimens and Data 32 13.0.0 Data Collection and Management Procedures 33 14.0.0 Quality Control 34 15.0.0 Statistical Considerations 34 16.2.0 Compensation 35 16.2.0 Compensation 36 17.1.0 Participant Safety Adverse Events & Problem Reporting 38 17.1.0 Participant Safety Adverse Events & Problem Reporting 38 17.1.1 Poorly controlled diabetes mellitus and related medical non-compliance 39 17.1.2 Poorly controlled diabetes mellitus and related medical non-compliance 39 17.1.3 Poorly controlled asthma/chronic obstructive pulmonary disease (COPD) 40 17.1.4 Alcohol Withdrawal 40 | | |
| 6.1.0 Ancillary studies, sub-study Objectives (HANDLS Scan) 19 6.1.1 Neuroimaging Sub-study Objectives (HANDLS Scan) 19 6.1.2 Predictors of Personality Sub-study Objectives. 20 6.1.3 Pennsylvania State University <i>pSITE</i> Roles and Responsibilities. 21 7.0.0 Expected Risks and Benefits 21 8.0.0 Eligibility. 22 9.0.0 Subject Enrollment 22 10.0.0 Study Design and Procedures 23 11.0.0 Procedure Description 27 12.0.0 Collection and Storing of Human Sample Specimens and Data 32 13.0.0 Data Collection and Management Procedures 33 14.0.0 Quality Control 34 15.0.0 Statistical Considerations 34 16.0.0 Regulatory Requirements 35 16.2.0 Compensation 36 17.1.0 Participant Safety & Adverse Events & Problem Reporting 38 17.1.1 Poorly controlled diabetes mellitus and related medical non-compliance 38 17.1.2 Poorly controlled diabetes mellitus and related medical non-compliance 39 17.1.3 Poorly controlled diabetes mellitus and related medical non-compliance 39 17.1.4 Alcohol Withdrawal 40 17.1.5 Seizure Disorder 40 | - | |
| 6.1.1 Neuroimaging Sub-study Objectives (HANDLS Scan) 19 6.1.2 Predictors of Personality Sub-study Objectives. 20 6.1.3 Pennsylvania State University <i>pSITE</i> Roles and Responsibilities. 21 7.0.0 Expected Risks and Benefits 21 8.0.0 Eligibility. 22 9.0.0 Subject Enrollment 22 9.0.0 Study Design and Procedures 23 11.0.0 Procedure Description 27 12.0.0 Collection and Storing of Human Sample Specimens and Data 32 13.0.0 Data Collection and Management Procedures 33 14.0.0 Quality Control 34 15.0.0 Statistical Considerations. 34 16.0.0 Regulatory Requirements 35 16.2.0 Compensation 36 17.0.0 Participant Safety, Adverse Events & Problem Reporting 38 17.1.1 Poorly controlled hypertension and related medical non-compliance 39 17.1.2 Poorly controlled asthma/chronic obstructive pulmonary disease (COPD) 40 17.1.3 Poorly controlled asthma/chronic obstructive pulmonary disease (COPD) 40 < | 6.1.0 Ancillary studies, sub-studies and <i>pSITEs</i> | 19 |
| 6.1.2 Predictors of Personality Sub-study Objectives. .20 6.1.3 Pennsylvania State University <i>pSITE</i> Roles and Responsibilities. .21 7.0.0 Expected Risks and Benefits .22 9.0.0 Subject Enrollment .22 9.0.0 Subject Enrollment .22 9.0.0 Study Design and Procedures .23 11.0.0 Procedure Description .27 12.0.0 Collection and Storing of Human Sample Specimens and Data .32 13.0.0 Data Collection and Management Procedures .33 14.0.0 Quality Control .34 15.0.0 Statistical Considerations. .34 16.0.0 Regulatory Requirements .35 16.2.0 Compensation .36 16.3.0 Subject Confidentiality .37 17.0.0 Participant Safety, Adverse Events & Problem Reporting .38 17.1.1 Poorly controlled hypertension and related medical non-compliance .39 17.1.2 Poorly controlled aibetes mellitus and related medical non-compliance .39 17.1.2 Poorly controlled aibetes mellitus and related medical non-compliance .39 | | |
| 6.1.3 Pennsylvania State University <i>pSITE</i> Roles and Responsibilities. 7.0.0 Expected Risks and Benefits 21 8.0.0 Eligibility. 22 9.0.0 Subject Enrollment 22 10.0.0 Study Design and Procedures 23 11.0.0 Procedure Description 27 12.0.0 Collection and Storing of Human Sample Specimens and Data 32 13.0.0 Data Collection and Management Procedures 33 14.0.0 Quality Control 34 15.0.0 Statistical Considerations 34 16.0.0 Regulatory Requirements 35 16.1.0 Informed Consent 35 16.2.0 Compensation 36 16.3.0 Subject Confidentiality 37 17.0.0 Participant Safety, Adverse Events & Problem Reporting 38 17.1.1 Poorly controlled hypertension and related medical non-compliance 38 17.1.2 Poorly controlled aibtma/chronic obstructive pulmonary disease (COPD) 40 17.1.3 Poorly controlled asthma/chronic obstructive pulmonary disease (COPD) 40 17.1.5 Poiorly controlled asthma | | |
| 8.0.0 Eligibility.229.0.0 Subject Enrollment.2210.0.0 Study Design and Procedures2311.0.0 Procedure Description2712.0.0 Collection and Storing of Human Sample Specimens and Data3213.0.0 Data Collection and Management Procedures3314.0.0 Quality Control3415.0.0 Statistical Considerations3416.0.0 Regulatory Requirements3516.1.0 Informed Consent3516.2.0 Compensation3616.3.0 Subject Confidentiality3717.0.0 Participant Safety, Adverse Events & Problem Reporting3817.1.1 Poorly controlled hypertension and related medical non-compliance3917.1.2 Poorly controlled diabetes mellitus and related medical non-compliance3917.1.3 Poorly controlled asthma/chronic obstructive pulmonary disease (COPD)4017.1.4 Alcohol Withdrawal4017.1.5 Seizure Disorder4017.2.0 Adverse Events and Unanticipated Problem Reporting4118.0.0 Site and Clinical Safety Monitoring Plan4119.0.0 Research with Investigational Drugs or Devices42 | | |
| 8.0.0 Eligibility.229.0.0 Subject Enrollment.2210.0.0 Study Design and Procedures2311.0.0 Procedure Description2712.0.0 Collection and Storing of Human Sample Specimens and Data3213.0.0 Data Collection and Management Procedures3314.0.0 Quality Control3415.0.0 Statistical Considerations3416.0.0 Regulatory Requirements3516.1.0 Informed Consent3516.2.0 Compensation3616.3.0 Subject Confidentiality3717.0.0 Participant Safety, Adverse Events & Problem Reporting3817.1.1 Poorly controlled hypertension and related medical non-compliance3917.1.2 Poorly controlled diabetes mellitus and related medical non-compliance3917.1.3 Poorly controlled asthma/chronic obstructive pulmonary disease (COPD)4017.1.4 Alcohol Withdrawal4017.1.5 Seizure Disorder4017.2.0 Adverse Events and Unanticipated Problem Reporting4118.0.0 Site and Clinical Safety Monitoring Plan4119.0.0 Research with Investigational Drugs or Devices42 | 7.0.0 Expected Risks and Benefits | 21 |
| 9.0.0 Subject Enrollment2210.0.0 Study Design and Procedures2311.0.0 Procedure Description2712.0.0 Collection and Storing of Human Sample Specimens and Data3213.0.0 Data Collection and Management Procedures3314.0.0 Quality Control3415.0.0 Statistical Considerations3416.0.0 Regulatory Requirements3516.1.0 Informed Consent3516.2.0 Compensation3616.3.0 Subject Confidentiality3717.0.0 Participant Safety, Adverse Events & Problem Reporting3817.1.1 Poorly controlled hypertension and related medical non-compliance3917.1.2 Poorly controlled diabetes mellitus and related medical non-compliance3917.1.3 Poorly controlled asthma/chronic obstructive pulmonary disease (COPD)4017.1.4 Alcohol Withdrawal4017.1.5 Seizure Disorder4017.2.0 Adverse Events and Unanticipated Problem Reporting4118.0.0 Site and Clinical Safety Monitoring Plan41 | - | |
| 10.0.0 Study Design and Procedures2311.0.0 Procedure Description2712.0.0 Collection and Storing of Human Sample Specimens and Data3213.0.0 Data Collection and Management Procedures3314.0.0 Quality Control3415.0.0 Statistical Considerations3416.0.0 Regulatory Requirements3516.1.0 Informed Consent3516.2.0 Compensation3616.3.0 Subject Confidentiality3717.0.0 Participant Safety, Adverse Events & Problem Reporting3817.1.1 Poorly controlled hypertension and related medical non-compliance3917.1.2 Poorly controlled asthma/chronic obstructive pulmonary disease (COPD)4017.1.4 Alcohol Withdrawal4017.1.5 Seizure Disorder4017.2.0 Adverse Events and Unanticipated Problem Reporting4118.0.0 Site and Clinical Safety Monitoring Plan4119.0.0 Research with Investigational Drugs or Devices42 | | |
| 11.0.0 Procedure Description 27 12.0.0 Collection and Storing of Human Sample Specimens and Data 32 13.0.0 Data Collection and Management Procedures 33 14.0.0 Quality Control 34 15.0.0 Statistical Considerations 34 16.0.0 Regulatory Requirements 35 16.1.0 Informed Consent 35 16.2.0 Compensation 36 16.3.0 Subject Confidentiality 37 17.0.0 Participant Safety, Adverse Events & Problem Reporting 38 17.1.1 Poorly controlled hypertension and related medical non-compliance 39 17.1.2 Poorly controlled asthma/chronic obstructive pulmonary disease (COPD) 40 17.1.4 Alcohol Withdrawal 40 17.1.5 Seizure Disorder 40 17.2.0 Adverse Events and Unanticipated Problem Reporting 41 18.0.0 Site and Clinical Safety Monitoring Plan 41 | | |
| 12.0.0 Collection and Storing of Human Sample Specimens and Data3213.0.0 Data Collection and Management Procedures3314.0.0 Quality Control3415.0.0 Statistical Considerations3416.0.0 Regulatory Requirements3516.1.0 Informed Consent3516.2.0 Compensation3616.3.0 Subject Confidentiality3717.0.0 Participant Safety, Adverse Events & Problem Reporting3817.1.1 Poorly controlled hypertension and related medical non-compliance3917.1.2 Poorly controlled diabetes mellitus and related medical non-compliance3917.1.3 Poorly controlled asthma/chronic obstructive pulmonary disease (COPD)4017.1.5 Seizure Disorder4017.2.0 Adverse Events and Unanticipated Problem Reporting4118.0.0 Site and Clinical Safety Monitoring Plan41 | | |
| 13.0.0 Data Collection and Management Procedures3314.0.0 Quality Control3415.0.0 Statistical Considerations3416.0.0 Regulatory Requirements3516.1.0 Informed Consent3516.2.0 Compensation3616.3.0 Subject Confidentiality3717.0.0 Participant Safety, Adverse Events & Problem Reporting3817.1.1 Poorly controlled hypertension and related medical non-compliance3817.1.2 Poorly controlled diabetes mellitus and related medical non-compliance3917.1.3 Poorly controlled asthma/chronic obstructive pulmonary disease (COPD)4017.1.5 Seizure Disorder4017.2.0 Adverse Events and Unanticipated Problem Reporting4118.0.0 Site and Clinical Safety Monitoring Plan42 | | |
| 14.0.0 Quality Control3415.0.0 Statistical Considerations3416.0.0 Regulatory Requirements3516.1.0 Informed Consent3516.2.0 Compensation3616.3.0 Subject Confidentiality3717.0.0 Participant Safety, Adverse Events & Problem Reporting3817.1.0 Participant Safety & Intent to Treat3817.1.1 Poorly controlled hypertension and related medical non-compliance3917.1.2 Poorly controlled diabetes mellitus and related medical non-compliance3917.1.3 Poorly controlled asthma/chronic obstructive pulmonary disease (COPD)4017.1.5 Seizure Disorder4017.2.0 Adverse Events and Unanticipated Problem Reporting4118.0.0 Site and Clinical Safety Monitoring Plan41 | | |
| 15.0.0 Statistical Considerations3416.0.0 Regulatory Requirements3516.1.0 Informed Consent3516.2.0 Compensation3616.3.0 Subject Confidentiality3717.0.0 Participant Safety, Adverse Events & Problem Reporting3817.1.0 Participant Safety & Intent to Treat3817.1.1 Poorly controlled hypertension and related medical non-compliance3917.1.2 Poorly controlled diabetes mellitus and related medical non-compliance3917.1.3 Poorly controlled asthma/chronic obstructive pulmonary disease (COPD)4017.1.4 Alcohol Withdrawal4017.1.5 Seizure Disorder4017.2.0 Adverse Events and Unanticipated Problem Reporting4118.0.0 Site and Clinical Safety Monitoring Plan4119.0.0 Research with Investigational Drugs or Devices42 | | |
| 16.0.0 Regulatory Requirements3516.1.0 Informed Consent3516.2.0 Compensation3616.3.0 Subject Confidentiality3717.0.0 Participant Safety, Adverse Events & Problem Reporting3817.1.0 Participant Safety & Intent to Treat3817.1.1 Poorly controlled hypertension and related medical non-compliance3917.1.2 Poorly controlled diabetes mellitus and related medical non-compliance3917.1.3 Poorly controlled asthma/chronic obstructive pulmonary disease (COPD)4017.1.5 Seizure Disorder4017.2.0 Adverse Events and Unanticipated Problem Reporting4118.0.0 Site and Clinical Safety Monitoring Plan4119.0.0 Research with Investigational Drugs or Devices42 | | |
| 16.1.0 Informed Consent3516.2.0 Compensation3616.3.0 Subject Confidentiality3717.0.0 Participant Safety, Adverse Events & Problem Reporting3817.1.0 Participant Safety & Intent to Treat3817.1.1 Poorly controlled hypertension and related medical non-compliance3817.1.2 Poorly controlled diabetes mellitus and related medical non-compliance3917.1.3 Poorly controlled asthma/chronic obstructive pulmonary disease (COPD)4017.1.4 Alcohol Withdrawal4017.1.5 Seizure Disorder4017.2.0 Adverse Events and Unanticipated Problem Reporting4118.0.0 Site and Clinical Safety Monitoring Plan4119.0.0 Research with Investigational Drugs or Devices42 | | |
| 16.2.0 Compensation3616.3.0 Subject Confidentiality3717.0.0 Participant Safety, Adverse Events & Problem Reporting3817.1.0 Participant Safety & Intent to Treat3817.1.1 Poorly controlled hypertension and related medical non-compliance3817.1.2 Poorly controlled diabetes mellitus and related medical non-compliance3917.1.3 Poorly controlled asthma/chronic obstructive pulmonary disease (COPD)4017.1.4 Alcohol Withdrawal4017.1.5 Seizure Disorder4017.2.0 Adverse Events and Unanticipated Problem Reporting4118.0.0 Site and Clinical Safety Monitoring Plan4119.0.0 Research with Investigational Drugs or Devices42 | | |
| 16.3.0 Subject Confidentiality3717.0.0 Participant Safety, Adverse Events & Problem Reporting3817.1.0 Participant Safety & Intent to Treat3817.1.1 Poorly controlled hypertension and related medical non-compliance3817.1.2 Poorly controlled diabetes mellitus and related medical non-compliance3917.1.3 Poorly controlled asthma/chronic obstructive pulmonary disease (COPD)4017.1.4 Alcohol Withdrawal4017.1.5 Seizure Disorder4017.2.0 Adverse Events and Unanticipated Problem Reporting4118.0.0 Site and Clinical Safety Monitoring Plan4119.0.0 Research with Investigational Drugs or Devices42 | | |
| 17.0.0 Participant Safety, Adverse Events & Problem Reporting 38 17.1.0 Participant Safety & Intent to Treat 38 17.1.1 Poorly controlled hypertension and related medical non-compliance. 38 17.1.2 Poorly controlled diabetes mellitus and related medical non-compliance. 39 17.1.3 Poorly controlled asthma/chronic obstructive pulmonary disease (COPD). 40 17.1.4 Alcohol Withdrawal. 40 17.2.0 Adverse Events and Unanticipated Problem Reporting 41 18.0.0 Site and Clinical Safety Monitoring Plan. 41 19.0.0 Research with Investigational Drugs or Devices 42 | | |
| 17.1.0 Participant Safety & Intent to Treat3817.1.1 Poorly controlled hypertension and related medical non-compliance | | |
| 17.1.0 Participant Safety & Intent to Treat3817.1.1 Poorly controlled hypertension and related medical non-compliance | 17.0.0 Participant Safety, Adverse Events & Problem Reporting | 38 |
| 17.1.2 Poorly controlled diabetes mellitus and related medical non-compliance | 17.1.0 Participant Safety & Intent to Treat | 38 |
| 17.1.3 Poorly controlled asthma/chronic obstructive pulmonary disease (COPD)40 17.1.4 Alcohol Withdrawal | | |
| 17.1.4 Alcohol Withdrawal 40 17.1.5 Seizure Disorder 40 17.2.0 Adverse Events and Unanticipated Problem Reporting 41 18.0.0 Site and Clinical Safety Monitoring Plan 41 19.0.0 Research with Investigational Drugs or Devices 42 | | |
| 17.1.5 Seizure Disorder | | |
| 17.2.0 Adverse Events and Unanticipated Problem Reporting4118.0.0 Site and Clinical Safety Monitoring Plan4119.0.0 Research with Investigational Drugs or Devices42 | | |
| 18.0.0 Site and Clinical Safety Monitoring Plan | | |
| 19.0.0 Research with Investigational Drugs or Devices | | |
| | 18.0.0 Site and Clinical Safety Monitoring Plan | 41 |
| 20.0.0 References | 19.0.0 Research with Investigational Drugs or Devices | 42 |
| | 20.0.0 References | 45 |

1.0.0 Statement of Compliance

The HANDLS study will be conducted in accordance with the design and specific provisions of this IRB-approved protocol, in accordance with the ethical principles that have their origin in the Declaration of Helsinki, the requirements set forth in the US code of Federal Regulation applicable to clinical studies (45 CFR 46, parts A through D) concerning informed consent and IRB regulations; and in compliance with the International Conference on Harmonization's guidelines for Good Clinical Practices (ICH GCP). The Principal Investigator will assure that no deviation from, or changes to the protocol will take place without prior agreement from the sponsor and documented approval from the IRB, except where necessary to eliminate an immediate hazard(s) to the study participants. The Principal Investigator will promptly report to the IRB and the sponsor any changes in research activity and all unanticipated problems involving risk to human subjects, or others.

2.0.0 List of Abbreviations

| MRVs Medical Research Vehicles SES socioeconomic status MRI magnetic resonance imaging DXA Dual-energy X-ray absorptiometry DNA deoxyribonucleic acid AA African American DTI deffusion tensor imaging ADC apparent diffusion coefficient SOP Standard Operating Procedures SSB single strand breaks DRC DNA repair capacity SNP single nucleotide polymorphism GWAS genome wide association study COGENT Continental Origins and Genetic Epidemiology Network CARe Candidate gene Association Resource consortium NHANES The National Health and Nutrition Examination Survey CKD chronic kidney disease ESRD end stage renal disease FA fractional anisotropy GM gray matter WM white matter T2DM grey 2 Diabetes Mellitus UMBC University of Maryland Baltimore County MINI McGill Illness Narrative Interview | HANDLS | Healthy Aging in Neighborhoods of Diversity across the Life Span |
|---|--------|--|
| SES socioeconomic status MRI magnetic resonance imaging DXA Dual-energy X-ray absorptiometry DNA | | |
| MRI magnetic resonance imaging DXA Dual-energy X-ray absorptiometry DNA deoxyribonucleic acid AA African American DTI diffusion tensor imaging ADC apparent diffusion coefficient SOP Standard Operating Procedures SSB single strand breaks DRC DNA repair capacity SNP single nucleotide polymorphism GWAS genome wide association study COGENT Continental Origins and Genetic Epidemiology Network CARe Candidate gene Association Resource consortium NHANES The National Health and Nutrition Examination Survey CKD chronic kidney disease ESRD end stage renal disease FA fractional anisotropy GM gray matter WM white matter T2DM Type 2 Diabetes Mellitus UMBC University of Maryland Baltimore County MINI McGill Illness Narrative Interview HIV human immunodeficiency virus FTA fast technology for analysis mRNA messenger ribonucleic a | | |
| DXA Dual-energy X-ray absorptiometry DNA | | |
| DNA | | 0 0 0 |
| AA. African American DTI. | | |
| DTI diffusion tensor imaging ADC apparent diffusion coefficient SOP Standard Operating Procedures SSB single strand breaks DRC DNA repair capacity SNP single nucleotide polymorphism GWAS genome wide association study COGENT Continental Origins and Genetic Epidemiology Network CARe Candidate gene Association Resource consortium NHANES The National Health and Nutrition Examination Survey CKD chronic kidney disease ESRD end stage renal disease FA fractional anisotropy GM gray matter WM white matter T2DM Type 2 Diabetes Mellitus UMBC University of Maryland Baltimore County MINI McGill Illness Narrative Interview HIV human immunodeficiency virus FTA fast technology for analysis mRNA messenger ribonucleic acid AMPM Automated Multiple Pass Method REALM Rapid Estimate of Adult Literacy WRAT Wide Range Achievement Test IVA <t< td=""><td></td><td></td></t<> | | |
| ADC apparent diffusion coefficient SOP Standard Operating Procedures SSB single strand breaks DRC DNA repair capacity SNP single nucleotide polymorphism GWAS genome wide association study COGENT Continental Origins and Genetic Epidemiology Network CARe Candidate gene Association Resource consortium NHANES The National Health and Nutrition Examination Survey CKD chronic kidney disease ESRD end stage renal disease FA fractional anisotropy GM gray matter WM white matter T2DM Type 2 Diabetes Mellitus UMBC University of Maryland Baltimore County MINI McGill Illness Narrative Interview HIV human immunodeficiency virus FTA fast technology for analysis mRNA messenger ribonucleic acid AMPM Automated Multiple Pass Method REALM Rapid Estimate of Adult Literacy WRAT Wide Range Achievement Test IVA Instant Vertebral Assessment mrem | | |
| SOP Standard Operating Procedures SSB single strand breaks DRC DNA repair capacity SNP single nucleotide polymorphism GWAS genome wide association study COGENT Continental Origins and Genetic Epidemiology Network CARe Candidate gene Association Resource consortium NHANES The National Health and Nutrition Examination Survey CKD .chronic kidney disease ESRD .end stage renal disease FA .fractional anisotropy GM .gray matter WM .white matter T2DM Type 2 Diabetes Mellitus UMBC .University of Maryland Baltimore County MINI McGill Illness Narrative Interview HIV .human immunodeficiency virus FTA fast technology for analysis mRNA .messenger ribonucleic acid AMPM Automated Multiple Pass Method REALM .Rapid Estimate of Adult Literacy WRAT .Wide Range Achievement Test IVA .Instant Vertebral Assessment mrem .millirem ATM .au | | |
| SSB | | |
| DRCDNA repair capacitySNPsingle nucleotide polymorphismGWASgenome wide association studyCOGENTContinental Origins and Genetic Epidemiology NetworkCAReCandidate gene Association Resource consortiumNHANESThe National Health and Nutrition Examination SurveyCKDchronic kidney diseaseESRDend stage renal diseaseFAfractional anisotropyGMgray matterWMwhite matterT2DMType 2 Diabetes MellitusUMBCUniversity of Maryland Baltimore CountyMINIMcGill Illness Narrative InterviewHIVhuman immunodeficiency virusFTAfast technology for analysismRNAmessenger ribonucleic acidAMPMAutomated Multiple Pass MethodREALMRapid Estimate of Adult LiteracyWRATWide Range Achievement TestIVAInstant Vertebral AssessmentmremmilliremATMautomated teller machineFDAFood and Drug AdministrationNIANational Institute on AgingNIHNational Institutes of Health | | |
| SNP | | |
| GWAS | | |
| COGENTContinental Origins and Genetic Epidemiology NetworkCAReCandidate gene Association Resource consortiumNHANESThe National Health and Nutrition Examination SurveyCKDchronic kidney diseaseESRDend stage renal diseaseFAfractional anisotropyGMgray matterWMwhite matterT2DMType 2 Diabetes MellitusUMBCUniversity of Maryland Baltimore CountyMINIMcGill Illness Narrative InterviewHIVhuman immunodeficiency virusFTAfast technology for analysismRNAmessenger ribonucleic acidAMPMAutomated Multiple Pass MethodREALMRapid Estimate of Adult LiteracyWRATWide Range Achievement TestIVAInstant Vertebral AssessmentmremmilliremATMautomated teller machineFDAFood and Drug AdministrationNIANational Institute on AgingNIHNational Institutes of Health | | |
| CAReCandidate gene Association Resource consortium NHANESThe National Health and Nutrition Examination Survey CKDchronic kidney disease ESRDend stage renal disease FAfractional anisotropy GMgray matter WMwhite matter T2DMType 2 Diabetes Mellitus UMBCUniversity of Maryland Baltimore County MINIMcGill Illness Narrative Interview HIVhuman immunodeficiency virus FTAfast technology for analysis mRNAmessenger ribonucleic acid AMPMAutomated Multiple Pass Method REALMRapid Estimate of Adult Literacy WRATWide Range Achievement Test IVAInstant Vertebral Assessment mremmillirem ATMautomated teller machine FDAFood and Drug Administration NIANational Institute on Aging NIHNational Institutes of Health | | • |
| NHANESThe National Health and Nutrition Examination SurveyCKDchronic kidney diseaseESRDend stage renal diseaseFAfractional anisotropyGMgray matterWMwhite matterT2DMType 2 Diabetes MellitusUMBCUniversity of Maryland Baltimore CountyMINIMcGill Illness Narrative InterviewHIVhuman immunodeficiency virusFTAfast technology for analysismRNAmessenger ribonucleic acidAMPMAutomated Multiple Pass MethodREALMRapid Estimate of Adult LiteracyWRATWide Range Achievement TestIVAInstant Vertebral AssessmentmremmilliremATMautomated teller machineFDAFood and Drug AdministrationNIANational Institute on AgingNIHNational Institutes of Health | | |
| CKD | | |
| ESRDend stage renal diseaseFAfractional anisotropyGMgray matterWMwhite matterT2DMType 2 Diabetes MellitusUMBCUniversity of Maryland Baltimore CountyMINIMcGill Illness Narrative InterviewHIVhuman immunodeficiency virusFTAfast technology for analysismRNAmessenger ribonucleic acidAMPMAutomated Multiple Pass MethodREALMRapid Estimate of Adult LiteracyWRATWide Range Achievement TestIVAInstant Vertebral AssessmentmremmilliremATMautomated teller machineFDAFood and Drug AdministrationNIANational Institute on AgingNIHNational Institutes of Health | | |
| GM | | - |
| WMwhite matterT2DMType 2 Diabetes MellitusUMBCUniversity of Maryland Baltimore CountyMINIMcGill Illness Narrative InterviewHIVhuman immunodeficiency virusFTAfast technology for analysismRNAmessenger ribonucleic acidAMPMAutomated Multiple Pass MethodREALMRapid Estimate of Adult LiteracyWRATWide Range Achievement TestIVAInstant Vertebral AssessmentmremmilliremATMautomated teller machineFDAFood and Drug AdministrationNIANational Institute on AgingNIHNational Institutes of Health | FA | fractional anisotropy |
| T2DM.Type 2 Diabetes MellitusUMBC.University of Maryland Baltimore CountyMINIMcGill Illness Narrative InterviewHIVhuman immunodeficiency virusFTA.fast technology for analysismRNA.messenger ribonucleic acidAMPMAutomated Multiple Pass MethodREALM.Rapid Estimate of Adult LiteracyWRAT.Wide Range Achievement TestIVAInstant Vertebral AssessmentmremmilliremATM.automated teller machineFDAFood and Drug AdministrationNIANational Institute on AgingNIHNational Institutes of Health | GM | gray matter |
| UMBCUniversity of Maryland Baltimore CountyMINIMcGill Illness Narrative InterviewHIVhuman immunodeficiency virusFTAfast technology for analysismRNAmessenger ribonucleic acidAMPMAutomated Multiple Pass MethodREALMRapid Estimate of Adult LiteracyWRATWide Range Achievement TestIVAInstant Vertebral AssessmentmremmilliremATMautomated teller machineFDAFood and Drug AdministrationNIANational Institute on AgingNIHNational Institutes of Health | WM | white matter |
| MINIMcGill Illness Narrative InterviewHIVhuman immunodeficiency virusFTAfast technology for analysismRNAmessenger ribonucleic acidAMPMAutomated Multiple Pass MethodREALMRapid Estimate of Adult LiteracyWRATWide Range Achievement TestIVAInstant Vertebral AssessmentmremmilliremATMautomated teller machineFDAFood and Drug AdministrationNIANational Institute on AgingNIHNational Institutes of Health | T2DM | Type 2 Diabetes Mellitus |
| HIV | UMBC | University of Maryland Baltimore County |
| FTAfast technology for analysismRNAmessenger ribonucleic acidAMPMAutomated Multiple Pass MethodREALMRapid Estimate of Adult LiteracyWRATWide Range Achievement TestIVAInstant Vertebral AssessmentmremmilliremATMautomated teller machineFDAFood and Drug AdministrationNIANational Institute on AgingNIHNational Institutes of Health | MINI | McGill Illness Narrative Interview |
| mRNAmessenger ribonucleic acidAMPMAutomated Multiple Pass MethodREALMRapid Estimate of Adult LiteracyWRATWide Range Achievement TestIVAInstant Vertebral AssessmentmremmilliremATMautomated teller machineFDAFood and Drug AdministrationNIANational Institute on AgingNIHNational Institutes of Health | HIV | human immunodeficiency virus |
| AMPMAutomated Multiple Pass MethodREALMRapid Estimate of Adult LiteracyWRATWide Range Achievement TestIVAInstant Vertebral AssessmentmremmilliremATMautomated teller machineFDAFood and Drug AdministrationNIANational Institute on AgingNIHNational Institutes of Health | FTA | fast technology for analysis |
| REALMRapid Estimate of Adult LiteracyWRATWide Range Achievement TestIVAInstant Vertebral AssessmentmremmilliremATMautomated teller machineFDAFood and Drug AdministrationNIANational Institute on AgingNIHNational Institutes of Health | mRNA | messenger ribonucleic acid |
| WRATWide Range Achievement Test IVAInstant Vertebral Assessment mremmillirem ATMautomated teller machine FDAFood and Drug Administration NIANational Institute on Aging NIHNational Institutes of Health | | |
| IVA Instant Vertebral Assessment mrem millirem ATM automated teller machine FDA Food and Drug Administration NIA National Institute on Aging NIH National Institutes of Health | REALM | Rapid Estimate of Adult Literacy |
| mremmillirem ATMautomated teller machine FDAFood and Drug Administration NIANational Institute on Aging NIHNational Institutes of Health | | |
| ATMautomated teller machine FDAFood and Drug Administration NIANational Institute on Aging NIHNational Institutes of Health | | |
| FDAFood and Drug Administration NIANational Institute on Aging NIHNational Institutes of Health | mrem | millirem |
| NIANational Institute on Aging NIHNational Institutes of Health | | |
| NIHNational Institutes of Health | FDA | Food and Drug Administration |
| | | |
| OHRPOffice of Human Research Protection | | |
| | OHRP | Office of Human Research Protection |

3.0.0 Protocol Summary

| Healthy Aging in Neighborhood | Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) – Wave 7 | | |
|-------------------------------|--|--|--|
| Short Title: | HANDLS | | |
| Conducted by: | National Institute on Aging, Intramural Research Program, Laboratory of Epidemiology and Population Sciences, Health Disparities Research Section | | |
| Principal Investigator: | Michele K. Evans, M.D., p: 410-558-8573 email: EvansM@grc.nia.nih.gov | | |
| Sample Size: | 3720 | | |
| Accrual Ceiling: | 4000 | | |
| Study Population: | The baseline HANDLS sample consists of 3720 community- dwelling African American and white adults aged 30-64. Participants were drawn from 13 neighborhoods (groups of contiguous census tracts) in Baltimore City, sampling representatively across a wide range of socioeconomic and income circumstances. | | |
| Accrual Period: | 2004-2009 | | |
| Study Design: | The heuristic study design is a factorial cross of four factors: age, sex, race, and SES with approximately equal numbers of subjects per "cell" (Figure 2 on page 26). HANDLS is planned as a 20-year longitudinal study of the 3720 individuals accrued (Figure 3 on page 26). Using our mobile medical research vehicles, we are revisiting each census tract for 2-3 months over the next 3 years. | | |
| Study Duration: | Start Date: 2004; End Date: 2024 | | |
| Primary Objective: | The primary objective of HANDLS is to conduct a longitudinal study of minority health, aging, and health disparities focused on investigating the differential influences of race and socioeconomic status on health in an urban population. | | |

4.0.0 Précis

The Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study is an interdisciplinary, community-based, prospective longitudinal epidemiologic study examining the influences of race and socioeconomic status (SES) on the development of age-related health disparities among socioeconomically diverse African Americans and whites in Baltimore. This study investigates whether health disparities develop or persist due to differences in SES, differences in race, or their interaction. Planned as a 20-year longitudinal study, HANDLS is unique because it assesses physical parameters as well as evaluating genetic, biologic, demographic, and psychosocial parameters of African American and white participants over a wide range of socioeconomic statuses. HANDLS also employs novel research tools, mobile medical research vehicles, in hopes of improving participation rates and retention among nontraditional research participants. The domains of the HANDLS study include: nutrition, cognition, biologic biomarkers, body composition and bone quality, physical function and performance, psychology, genomics, neighborhood environment and cardiovascular disease. Utilizing data from these study domains will facilitate an understanding of selected underlying factors of persistent black-white health disparities in overall longevity, cardiovascular disease, and cognitive decline.

HANDLS recruited a fixed cohort as an area probability sample of Baltimore City from August 2004 through November 2009 as Wave 1 (Figure 1). HANDLS Wave 2 entitled The Association of Personality and Socioeconomic status with Health Status - An Interim Follow-up Study began in June 2006 under a separate protocol. It was designed as a follow-up telephone interview approximately 18 months after the initial examination (Wave 1) was complete. Wave 2 provided interim contact with study participants, and important interim information regarding their health. Now completed, waves 3, 4 and 5 were follow-up examinations visits to our mobile Medical Research Vehicles (MRVs). In September 2020, HANDLS initiated wave 6; telephone interviews and limited in-person visits as a COVID-centric protocol. The current protocol outlines Wave 7, the fourth follow-up examination and the participants' fifth visit to our mobile Medical Research Vehicles (MRVs). Planned as a follow-up after 3-4 years, Wave 7 consists of health examinations, questionnaires, sensory assessments (visual and olfactory), health literacy assessment, renal function assessments, environmental assessments, and for a sub-set of participants; structural MRIs, a personality inventory and an examination of sleep and cognition under separate protocols. HANDLS will resume in-person examinations with wave 7 in which we will prioritize contacting participants who were not seen in wave 5.




Figure 1. Present and projected HANDLS timeline

5.0.0 Background and Scientific Rationale

There are well-documented differences in health status among groups defined by age, race, ethnicity, and socioeconomic status (SES). Over the past decade or so, evidence from cross-sectional studies and nationally representative follow-ups suggests that there are persistent disparities among African Americans and other minority groups compared to Whites in morbidity¹⁻¹⁶ and mortality.^{15,17-21} This is particularly evident in the steadily growing divide between well-educated white men and women and less educated African Americans.²² Double jeopardy describes the constellation of health disparities conferred by old age and membership in a minority group.²³ Evidence suggests that there are unique disadvantages conferred by the combination of old age and minority status, ^{1-7,9,11-19,23-27} but the extent to which minority status is a direct cause of the disadvantage is unknown. Race, ethnicity, and SES are inextricably confounded in many studies. Membership in a minority group may be an indicator of the

combinations of other effects such as low income, poor education, environmental exposure to toxic compounds, and lack of occupational opportunities. Recent data also suggests declining life expectancy and increased premature mortality among low-SES whites ²⁸.

Independent of the effects of race and ethnicity, SES accounts for differences in the functional status associated with chronic disease, but has only a small role in predicting prevalence of chronic disease.¹⁶ Further complicating this relationship, physicians' assessments and treatment differ by race and sex.^{24,29} Addressing these disparities in health status requires data about the differences in risks for chronic disease associated with race, ethnicity, and SES in all groups regardless of their majority or minority standing.

The scientific objectives of HANDLS are to establish a single-site prospective longitudinal epidemiologic study of health disparities in socioeconomically diverse African Americans and whites residing in the city of Baltimore. Specifically, we designed HANDLS to disentangle the effects of race and SES on risk factors for morbidity and mortality, to examine the incidence and progression of pre-clinical disease, and to follow-up the development and persistence of health disparities, longitudinal health status, and health risks. The mechanisms or biologic and molecular pathways through which the health and longevity trajectories of individuals in American society are influenced are unknown at this time.

The present protocol focuses on predictors of change in cardiovascular function and fitness, risks for cerebrovascular conditions such as stroke, vascular dementia, and carotid stenosis, renal function, and pathological cognitive decline. We chose these specific areas as representing the health issues that are among the most prevalent, but least understood, in African Americans and low SES urban dwelling whites who have health burdens similar to African Americans. Specifically, we will measure heart function by EKG, muscle strength by grip strength, chair stand and single leg stand exercises, body composition by dual photon x-ray absorptiometry (DXA), cognitive performance with cognitive and neuropsychological tests, sensory functioning with the olfactory assessment, and the Marco refractometer NIDEK for visual acuity and the TRC NW400 Non-Mydriatic fundus camera TOPCON and the Optoview Optical Coherence Tomography (OCT) machine for fundal images, skin microbiota using a skin swab, environmental exposure to toxins by collecting toenail clippings, and neuroimaging parameters by structural MRI.

We assess each of these areas by separate procedures for which we will investigate crosssectional differences and longitudinal change within this sample and by comparison with other samples, particularly the National Health and Nutrition Examination Studies and other studies with which this study shares many procedures and tests. We will combine these measures in various ways to examine the risks for pathological outcomes such as stroke, dementia, and loss of functional independence.

6.0.0 Study Objectives

The primary objective of HANDLS is to conduct a longitudinal study of minority health and health disparities focused on investigating the differential influences of race and socioeconomic status on health in an urban population.

The scientific research questions for this interdisciplinary epidemiologic study of minority health and health disparities are:

(1) Do race and SES influence health disparities independently or do they interact with several factors (race, environmental or biologic factors, and cultural or lifestyle practices)?

- (2) What is the influence of SES and race on age-related declines in function in an urban population?
- (3) What is the influence of SES and race on the incidence and natural history of age-related disease?
- (4) Are there early biomarkers of age-related health disparities that may enhance our ability to prevent or ameliorate the severity of these diseases?

For specific systems we will test the following hypotheses during Wave 7 of HANDLS:

Cardiovascular. (1) There will be significantly greater decline in cardiovascular health status as a function of SES and race independent of the effects of age in both men and women; for example, left ventricular mass, an important cardiac risk factor, is greater in African Americans than whites and is greater in African Americans of lower SES as compared to age-matched African Americans with higher SES, in both men and women; (2) Endothelial dysfunction is known to be more prevalent among African Americans. We hypothesize that it will not only be more prevalent in African Americans but also in low SES whites and those with evidence of oxidative stress markers because poverty and oxidative stress will be important modulating factors of endothelial function; (3) low SES will also correlate with lower Ankle-Brachial Index (ABI) values and increased longitudinal risk of cardiovascular morbidity and mortality.

Body composition and bone quality. Compared to white adults of comparable age, African Americans have: (1) A higher proportion of fat to lean mass of the total body, trunk and extremities, and greater odds of meeting DXA-defined criteria for sarcopenia and sarcopenic obesity; (2) Faster loss of lean mass, greater accumulation of fat mass and greater increase in the proportion of fat to lean mass of the total body, trunk and extremities, and greater risk of transition to sarcopenia and sarcopenic obesity; (3) Faster and earlier decline in bone density; and, (4) These associations are correlated with, and perhaps mediated by, differences in health habits such as nutrition, physical activity, and alcohol consumption.

Cognition. The rates of decline of various cognitive abilities will be the same in all groups regardless of race, ethnicity, or SES.

Muscle Strength. (1) African Americans have the same trajectory of muscle loss as other ethnic or racial groups after accounting for differences in occupational history, nutrition, and body mass and composition; (2) All ethnic and racial groups will show the same relationships among changes in muscle strength, physical activity, and cardiovascular fitness regardless of socioeconomic factors, nutrition, and comorbid conditions such as diabetes; and, (3) The greater strength reductions at older ages among lower SES individuals will be attributable to their greater severity of chronic diseases.

Covariates. Other variables such as nutrition, environment and neighborhood effects, genetic make-up, family history, activity level, access to health care, prevalent medical, dental, sensory, psychiatric conditions, caregiving status, renal function, oxidative stress, and inflammatory status may modulate the effects of SES and race on cardiovascular, musculoskeletal, and cognitive functioning. For example:

Skin and Health Disparities. Skin Microbiota. The microbiome of individual organisms conveys information about health status. In humans, alterations in the human microbiome are associated with diabetes, auto-immune disease, cancer as well as allergies.³⁰ The skin microbiome harbor billions of microorganisms, approximately 1 million bacteria reside per square cm of human skin.³¹ The skin has a system of immune surveillance comprised of epithelial cells, lymphocytes, and antigen presenting cells. This system interdigitates with the innate and adaptive immune system.³² For example, skin microbiota can affect expression of the complement system, an important part of host defense and inflammation targeted at invading microbes.³³ The interaction of the skin microbiome with the immune system appears to underlie many skin disorders as well slow wound healing.³⁴ Chronic slow wound healing is associated with diabetes, vascular disease, obesity as well as aging.³⁵ Dysfunctional interaction of bacteria, fungi, mites, and viruses present on skin promote skin disease and chronic wounds. Clinically in the HANDLS population we have observed numerous examples of slow wound healing and would like to explore the role of the skin microbiome as a risk factor. We are particularly interested in exploring the effect of environment and host demographic factors on skin microbiota. This will allow us to help define normal healthy microbiota, how the skin microbiota interacts with the host immune system and most importantly whether there is any interaction between the skin microbiota and microbiota in other parts of the body.³⁶ We will sample by swabbing 4 areas of the upper extremities: inner aspect of the volar aspect and the antecubital fossae of both arms (~4 cm² area using a sterile cotton pledget soaked in sterile 0.15 NaCl with 0.1% Tween 20.³⁷ All samples will be stored -80° C.

Oxidative stress and inflammatory state. As a translational research study, HANDLS permits investigation of health disparities in terms of socioeconomic, socio-cultural, and psychosocial parameters. HANDLS allows us to define a medical/biologic phenotype that may be amenable to dissection by bench scientists examining the molecular aspects of aging, disease and disability. The early appearance and increased severity of age-associated disease among African Americans and low SES individuals suggests that the factors contributing to the emergence of health disparities may also induce a phenotype of 'accelerated aging'. While others have attributed this to racism and other socio-cultural factors, we seek to understand the underlying biologic, genetic, and environmental factors that may result in this phenotype that ultimately contributes to the disparate life expectancies for low-SES and minority sub-populations. The health disparities induced phenotype of accelerated aging may be biologically similar to heritable 'progeroid' syndromes whose manifestations include increased susceptibility to oxidative stress, premature accumulation of oxidative DNA damage, defects in DNA repair and higher levels of biomarkers of oxidative stress and inflammation. While genetic background, environmental and behavioral factors influence health outcomes in all populations over the lifespan, health disparities may be the end product of an accelerated trajectory of dysfunctional interactions of these factors in populations at high risk or with high levels of risk exposure. Oxidative DNA damage includes single strand breaks (SSBs) and oxidative base damage. An increased baseline level of oxidative DNA damage is associated with several age-related diseases including: cardiovascular disease ³⁸,

diabetes mellitus,³⁹ cancer,⁴⁰ neurodegenerative disease,⁴¹ and end-stage renal disease.⁴² The level of oxidative DNA damage depends on a variety of factors. They may include age,⁴⁰ environmental exposure to genotoxic factors,⁴³ smoking,⁴⁴ ethanol intake,⁴³ and intracellular and extracellular metabolism.⁴⁵

HANDLS examines this hypothesis by measuring biomarkers of oxidative stress and inflammation, assessing levels of the most widely studied oxidative DNA adducts. In addition, other important biomarkers of oxidative stress are being evaluated. Measures of inflammatory states include the pro-inflammatory cytokines, damage associated molecular pattern molecules like circulating mitochondrial DNA and C-reactive protein. Prospectively measuring biomarkers of oxidative stress in a longitudinal study may clarify whether oxidative stress plays a pivotal role in aging and in the development and or progression of age associated disease. It may also provide insights into the different trajectories of aging observed in individuals.

Genetics. Current technological advances in genotyping permit high throughput whole genome single nucleotide polymorphism (SNP) genotyping to proceed with the overall goal of examining the genetic contributions to the development of multi-gene complex clinical disorders. Of equal importance is the contribution this new knowledge will provide in furthering the examination of the genetics behind the differences in medicinal drug responses frequently seen in individuals as well as to the discovery of new drug targets for a range of diseases with persistently high morbidity and mortality. Our primary aim is to identify the genetic factors that are associated with age-associated health disparities. We hypothesize that the prevalence and severity of ageassociated disease in minority populations is related to in some cases genetic susceptibility factors. Genotyping will focus on identifying specific SNPs that may be related to disease susceptibility and or the severity of disease states and metabolic conditions that disproportionately affect this longitudinal cohort over the next 20 years. Examining the prevalence of these genetic polymorphisms is critical to understanding not only the association between the polymorphism and the disease but the molecular and biological functional outcome of these polymorphisms. Although race itself is not a definitive biologic factor but largely a proxy for social, cultural behavioral and environmental factors it is critically important for us to attempt to understand the role of genetic susceptibility to specific age-related heath disparities and clinical characteristics. The first step to gaining this understanding is to identify risk alleles for common diseases through genome wide association studies (GWAS). However, most of the early GWAS analyses failed to include diverse cohorts enriched for sub-populations at greatest risk. Therefore, inclusion of diverse population groups will hopefully enhance understanding of the effects of various genetic variants in different groups who may have different environmental exposures.

Whole genome SNP genotyping using the Illumina Infinium II platform for the first 1000 participants has been completed. Additional genotyping will take place using Illumina Neuro-X and EPIC chips. Planned work will proceed in conjunction with GWAS consortia including: the Continental Origins and Genetic Epidemiology Network (COGENT) and the Candidate–gene Association Resource consortium (CARe). Initial areas of research have focused on renal, metabolic, hematologic, and cardiovascular characteristics or conditions. Analysis of the data set is underway to determine genetic associations with hypertension, renal disease, cardiovascular disease, stroke and other age associated health disparities. In addition, other GWAS studies that have been completed focused on height, platelet count, water balance, and serum sodium

concentration. Supplementary genotyping and sequencing will be performed dependent on the availability of funds.

Epigenetics. The disproportionate incidence and mortality from age-associated disease may also result from epigenetic mechanisms such a DNA methylation. One theory of aging focuses on the role of genes and the epigenome in the development of the aging phenotype. We will examine the hypothesis that human disease and disability may result from DNA modifications that are not the result of changes in the coding sequence of genes. The clinical relevance of DNA methylation states in the development of age-related disease has yet to be understood on a population basis. There is variation in methylation states from individual to individual. This may be related to age, gender, environmental exposure, and other genetic factors. Is it possible that our hypothesized phenotype of accelerated aging phenotype seen in low SES and minority communities is related to epigenetic factors such as methylation? Using the Illumina EPIC chip, we will examine methylation states within this longitudinal cohort to attempt to understand whether genetic methylation states are associated with the premature development of ageassociated disease. We have chosen to employ DNA isolated from the lymphoid cells for this study. Our investigations will focus on identifying DNA methylation pattern factors that are associated with accelerated aging and the development of age-related health disparities conditions.

Environmental Exposure. To fully understand the transduction factors that lead to health disparities it is critical for us to understand the role that the environment may play for the interaction of the host with the environment is a fundamental source of disease. This is especially true in the context of health disparities where there are numerous reports that highlight disproportionate exposure for certain US sub-populations to environmental toxicants.⁴⁶ Poor, low resourced, economically disenfranchised minority communities are more frequently affected by higher that average levels of soil and air contamination by a variety of toxicants including lead, cadmium and arsenic. The role of environmental chemicals in health disparities is an area of active research because there is evidence that disproportionate exposure of selected toxins can be directly linked to specific health disparities. Renal disease is linked to environmental exposures of lead and cadmium at high levels. However, more recent data suggests that even chronic low levels of exposure may predispose to developing specific nephropathies, albuminuria and chronic kidney disease.⁴⁷ These low levels of exposure may not only be etiologic factors in renal disease but also promote disease progression of chronic kidney disease that may arise from other factors (i.e. diabetes mellitus, uncontrolled hypertension). Cumulative exposure to lead in adults leads to more rapid longitudinal changes in numerous measures of cognitive function suggesting that lead plays a role in accelerated cognitive aging.^{48,49} There is also a longitudinal association between zinc levels and diabetes incidence in young adults and a relationship between zinc levels and redox status in diabetes that may portend more significant disease.^{50,51} Selenium levels have also been linked with pre-diabetes, metabolic syndrome, and certain cancers.⁵² Arsenic levels have been linked with numerous poor health outcomes including cancer (skin, lung, bladder), cardiovascular disease and possibly diabetes mellitus.^{53,54} The links between the environment and health as well as the presence of environmental injustice among communities of color and among poor white communities provide a strong rationale for us to assess environmental exposures in our bi-racial socioeconomically diverse cohort.

Baltimore is home to many environmental hazards including polluting industries, a coal fired power plant, a coal disposal facility, and a trash incinerator among others. The trash incinerator alone emits lead, mercury, and dioxin into the air. Each of these industries in our urban setting results in higher levels of toxicants in the air and water creating environmental hazards that disproportionately occur in low income and minority communities in Baltimore many of which are the original 13 census segments from which HANDLS participants were recruited. Given the likelihood that our population cohort has been exposed to environmental toxicants, we would like to assess their exposure in the context of the observed age-related health disparities present in the cohort. We will examine possible long-term (1 year) cumulative exposures of several trace elements in HANDLS participants by collecting nail clippings from the distal edge of the nail plate on all 10 toes during their visit. Although chemical exposures can be quantified using blood and urine, these biofluids reflect short term exposures. We will assess chemical exposure using toenails because of their slow growth rate and lower rate of exposure to external contamination making them a better biomarker of chronic or longer-term exposure.⁵⁵⁻⁵⁷ Toenail trace elements may be used as biomarkers that might be linked to various health disparities. Chronic exposure to lead, cadmium, arsenic, mercury among other agents have been implicated in cognitive decline, cancer, cardiovascular disease as well as mortality and may be noninvasively monitored using toenail clippings.⁵⁸⁻⁶¹ We are particularly interested in assessing arsenic levels because arsenic affects epigenetic silencing, promoter methylation and DNA repair capacity which we can assess as part of other domains of the HANDLS study. Using stainless steel, single use latex free nail clippers participants will be asked to provide toenail clippings during their longitudinal visit at the MRV and during home visit for participants who do not come to the MRV for follow-up. We will also collect 10 milliliters of blood in trace metal free tubes. This is a minimal risk biomaterials collection. The major risks are incidental injury to the nail cuticle with a risk for bleeding or infection.

Renal function. The National Health and Nutrition Examination Survey (NHANES) reports that while chronic kidney disease (CKD) prevalence among Americans older than 20 years of age was 16.8%, rates for non-Hispanic Blacks and Mexican Americans were higher (19.9% and 18.7% respectively. This disparity is significantly highlighted when assessing the prevalence of stage 1 CKD. Prevalence of CKD 1 among non-Hispanic Blacks. The statistics for End-Stage Renal Disease (ESRD) mirror these disparities; African Americans have a 3.6 fold higher rate than whites and Hispanics have a 1.5 times higher prevalence rates than the U.S. non-Hispanic white population.⁶²

The risk factors for CKD are multifaceted and difficult to dissect; they include: hypertension, diabetes mellitus, smoking, race, age, obesity and heart disease⁶³. However, it is clear that other etiologic factors may also play a role including behavior, genetics, and the physical and sociologic environment as has been shown for ESRD ⁶⁴⁻⁶⁶. Because of the complexity of the factors that influence the development of chronic kidney disease and the significant impact CKD and ESRD have on quality of life, disability and life expectancy ⁶⁴⁻⁶⁸, we set out to examine predictive factors for CKD, including poverty, genetics, food security, diet, and race. In hopes of providing early identification of participants with CKD, to improve outcomes and awareness of CKD among participants, serum Cystatin C levels will be measured in each participant. Cystatin C has been selected because the literature suggests that it may provide a more accurate estimate of GFR, especially when GFR is only mildly depressed.⁶⁹ Additionally, Cystatin C has been

found to be a better predictor of cardiovascular mortality than creatinine among persons with mild CKD.

Caregiving. Health disparities may result from various forms of stress including psychological stress. Many studies have linked caregiving with significant levels of chronic stress for caregivers. This chronic stress is moderated by socioeconomic status, the condition and disabilities of the individual for whom care is provided, social support, and the age of the caregiver. Most of this research sampled primarily white caregivers. There remains a lack of research focused on middle and older aged, African-American women who are in multiple caregiving roles. We will examine the influence of multiple caregiving roles (i.e., occupancy of more than one caregiving role) on the physical and mental health outcomes of HANDLS participants. This aim is to gain greater understanding about the relation between multiple caregiving roles (i.e., occupancy of more than one caregiving role), and health status (physical and mental) among HANDLS participants. This proposed study could extend the caregiving literature in several ways. First, it will assess the influence of multiple caregiving roles on health status of caregivers, across race/ethnicity, class and gender. Previous studies lacked sample diversity and primarily focused on low-income African Americans.

Sensory Testing

Olfactory testing. Risk for dementia is associated with age⁷⁰, and there are significant and large disparities in the rates of dementia by race⁷¹ and socioeconomic status⁷². According to the Alzheimer's Association, African Americans are about twice as likely than whites to develop Alzheimer's disease, the most common form of dementia⁷³. African Americans are also less likely than whites to be diagnosed with dementia. When African Americans are diagnosed, their diagnosis is likely later in the course of the disease⁷³. Socioeconomic status, particularly the likelihood of adequate health insurance, complicates the identification of dementia because low educational attainment and low income are also risks for dementia⁷⁴. As a consequence of these racial and socioeconomic disparities in dementia, the Department of Health and Human Services established the goal of addressing health disparities as a priority for research aimed at preventing and treating Alzheimer's disease⁷⁵.

As a study of racial and socioeconomic health disparities in African Americans and whites, the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study has the opportunity to study the early signs and symptoms of dementia. We will administer the odor identification test Sniffin' Sticks, a well-validated and inexpensive instrument to measure olfactory function. Odor identification with Sniffin' Sticks is performed by holding an uncapped canister that resembles a marker pen 2 cm from participants' noses while asking them to sniff the odor. Deficits in odor identification using Sniffin' Sticks are associated with risk for dementia^{76,77}. The Brief Smell Identification Test (BSIT) will be administered as an alternative to Sniffin' Sticks when it is deemed unsafe to administer Sniffin' Sticks due to pandemic related safety requirements. The BSIT consists of 1 booklet with 12 scratch and sniff items per book (1 odorant per page; 12 questions total). To take this test, a participant scratches the odorant label on the page with a pencil, sniffs it, and identifies the odor. Above each label is a multiple-choice question asking the participant to identify the odor. There are four response items for each question. The participant can shade the bubble next to their response for each item.

There are no risks associated with administering Sniffin' Sticks or the BSIT. HANDLS participants who have decreased abilities to smell (hyposmia) or are unable to smell (anosmia) will be excluded.

Ocular Health (visual acuity and retinal pathological change). Given that there are notable health disparities in ocular diseases including glaucoma, diabetic retinopathy, and Age Related Macular Degeneration⁷⁸, we will begin to assess vision and refractive error in our participants as well as to assess retinal health and macular health by doing digital fundal photography using a nonmydriatic (non-dilation) camera that will allow us to assess markers of age and disease related retinal change. Although it is difficult to find data that captures the number of people affected by visual impairment in the United States, it has been estimated that perhaps as many as 142 million individuals over the age of 40 have visual impairment. The most common causes of the visual impairment include refractive error, age-related macular degeneration, cataract, diabetic retinopathy and glaucoma. Understanding and evaluating visual impairment is a critical part of health disparities research since poor eye health is associated with factors that contribute to already existing health inequities in low SES and minority populations. Poor vision is associated with increased risk for falls, social isolation as well as creating psychological stress that further enhances the adverse effects of already existing chronic medical condition⁷⁹. This research is in keeping with recommendation 1 of the National Academy of Sciences September 2016 report entitled Making Eve Health a Population Health Imperative: Vision for Tomorrow.

We will assess visual acuity using the Marco refractometer NIDEK auto refract/keratometer ARK/760A and obtain fundal images using the TRC NW400 Non-Mydriatic fundus camera TOPCON and the Optoview Optical Coherence Tomography (OCT) machine in collaboration with Dr. Emily Y. Chew, M.D., Deputy Director, Division of Epidemiology and Clinical Applications and Deputy Clinical Director, National Eye Institute. There are no risks associated with these tests. Some participants may find the light used during the digital photography of the fundus bright. This is a transient effect with no long-lasting sequalae. Blind participants will be excluded.

Health literacy. Examination of the underlying factors of health disparities requires investigation of health literacy among populations at risk. Health literacy is defined as "the degree to which individuals can obtain, process, and understand the basic information and services they need to make appropriate health decisions..."80 In 2004, the IOM estimated that almost 90 US adults million adults had low levels of health literacy.⁸¹ Work by multiple groups has linked health disparities to low levels of literacy and these disparities are not solely linked to income level, race or education levels.⁸²⁻⁸⁴ Older adults are also more likely to have low levels of health literacy as well as those with multiple chronic illnesses or co-morbid conditions.⁸⁵⁻⁸⁸ Reading and numerical skills are required to function effectively in health care environment. Inadequate health literacy affects several factors that may influence health disparities as well as severity of age-related conditions such as preventive care, medical compliance, and health care expenditures. Health literacy may also influence the recruitment and retention of low SES and minority individuals in clinical research. One of the gaps in our knowledge about reducing health disparities is how to modulate associated factors like health literacy to promote the reduction of health disparities. As many suggest, it is essential to integrate health literacy assessments in disparities research.89

We will assess health literacy in Wave 7 of HANDLS, using a short version of the REALM to examine its and to investigate the influence of race, sex, age, income, education and reading level on health literacy. We will also assess the associations of health literacy with chronic medical conditions, multiple co-morbidities, cognition, and symptoms of depression and other psychological factors. It provides an adequate evaluation of an individual's ability to read and understand health materials. Perhaps most significantly, we will use the health literacy data to develop appropriate HANDLS research study materials as well as health education messages tailored to our study population. Although we now assess all participant study materials for culturally competent and proficient communication as well as for readability using the Flesh-Kincaid Readability formula, it is likely that this additional information about health literacy levels will better inform our material preparation and review process. Given the very high smoking rates in our population, it is clear the standard health education we can add to the literature information that will improve health education messages for vulnerable, at risk populations.

Mobile Health. HANDLS will test the feasibility of providing cellular phones or small internet ready devices to determine whether the device will help to improve compliance with HANDLS physician recommended healthcare follow-up stemming from their HANDLS medical examination. We will send electronic reminders to participants about physician's treatment recommendations explaining the risks for further complications should their healthcare needs go untreated. We will also send general health education information. For difficult to track participants, we will test whether providing the device will assist in maintaining contact between study visits and whether providing appointment reminders improves retention rates among the most difficult to track HANDLS participants.

COVID-19 Infection and seroprevelance: factors influencing disparate outcomes. The COVID-19 pandemic underscores and brings to the forefront of the nation's consciousness the persistent and structurally enforced health disparities and health care inequities present in this country. The pandemic has had significantly disparate effects on AAs and the other similarly marginalized minority communities, Latinx and Native Americans. The existing health disparities in these populations in combination with the repeated levels of exposure to the virus through their occupations and other social determinates of health have led to SARS-CoV-2 infection incidence and mortality rates among AAs and Latinx 2-3 times that of whites in most metropolitan areas. To address this glaring health disparity and to examine the incidence, prevalence and additional risk factors present in these populations, it is critical to proactively test in neighborhoods with high social vulnerability indexes (SVI) as designated by the Centers for Disease Control and Prevention. High SVI portends low levels of resilience in communities when they are stressed by disasters and external stresses to include pandemic disease outbreaks. In 2016, the overall SVI score was for Baltimore City was 0.8364. The range for SVI is 0 for communities with the lowest vulnerability and 1 for those with high vulnerability and lowest resilience. Baltimore is a city at risk.

The Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study cohort is as a Baltimore-based, well-phenotyped group of socioeconomically diverse AAs and whites who have been longitudinally studied as a fixed cohort for 15 years⁹⁰ provides an ideal opportunity to examine critical risk factors in this pandemic. We have studied residents from

across the city of Baltimore including from the zip code within the State of Maryland, 21215, which has the highest rate of SARS-CoV-2 infection. Examining infection and seropositivity prevalence rates in AAs and whites with 15 years of longitudinal clinical, genomic, and psychosocial data is a unique opportunity to investigate the interaction of risk factors that further drive the differential COVID-19 health outcomes observed.

Specific Aims and Expected Results:

1. Examine the prevalence and clinical manifestations of COVID-19 infection and seroprevalence in a community-based cohort of socioeconomically diverse urban AA and low socioeconomic status (SES) Baltimore residents to understand pre-symptomatic and asymptomatic carrier states in high risk populations, to determine the extent of previous infection and the duration of SARS-CoV-2 antibody persistence. The prevalence of antibodies to SARS-CoV-2 was measured in 3,330 adults and children in Santa Clara County California using the Premier Biotech Serology Test, a lateral flow immunoassay⁹¹. The seroprevalence was between 2.49 and 4.16%. This suggests that the infection in this California county may be more widespread than the number of confirmed cases indicates. It also suggests that the virus may have been circulating earlier than suspected and that there could be many in the community who have already seroconverted. However, among the serious limitations in this yet unpublished work, is this study's failure to sample a representative segment of the racial/ethnic minority community as well as low SES individuals and the use of an unapproved and unvalidated antibody test. Models of SARS-CoV-2 transmission suggest that there may be a second recurrent outbreak next flu season (fall/winter)⁹². Therefore, longitudinal serological studies should be performed to determine the extent of residual seropositivity as well as the duration of any immunity that may accompany seropositivity. This is a critically important factor to predict and prepare for the possible impact of the 'second pandemic wave' in this group of aging, urban dwelling AAs, whites and low SES individuals with significant morbidities that are at increased risk of mortality from SARS-CoV-2. The immune system's response to SARS-CoV-2 infection is through the adaptive immune response ⁹³. Those infected with COVID-19 must develop a specific adaptive immune response to eliminate the virus and avoid morbidity and mortality. This response involves production of α interferon, TNF- α , as well as several interleukins including: IL-6 and IL-12 as well as the development of CD8+ specific cytotoxic T-Cells ⁹⁴. If this response is ineffective, severe disease may result. The severity of COVID-19 disease among AAs could be related to the effectiveness of the adaptive immune response. In HANDLS, since SES conditions influence the prevalence of early and persistent infection by Cytomegalovirus (CMV) this response may be less than robust. It is well-known that early CMV infection may influence the immune profile to resemble immunosenescence ⁹⁵. It is possible that one of the reasons that AAs, the aged, and those with 2 or more co-morbidities have poor outcomes may be a sluggish or incomplete adaptive immune response. In HANDLS participants, the issue of immunosenescence is important because the accelerated aging phenotype of health disparities is present in a large portion of the cohort. Though we are early in the pandemic and the disease presentation associated with infection by SARS-CoV-2 continues to evolve, there may be many presentations and or stages of the disease. Some individuals present as asymptomatic or presymptomatic but positive for the virus. In this stage, they may or may not pass on to others so it is possible to be asymptomatic yet virus positive. This may be during the incubation period but it remains to be seen whether this is also a true carrier state that is not accompanied by significant

clinical manifestations and illness. There may also be a COVID-19 positive state associated with symptoms that are non-severe and do not progress. Finally, there is a COVID-19 positive state characterized by high viral load and progression to severe respiratory symptoms. Do these stages or presentations exist among these at highest risk for the disease as well?

We will perform SARS-CoV-2 viral testing, cross sectional and longitudinal seroprevalence assays, CMV antibody testing, clinical lab assays known to be associated with viral infection including ferritin, d-dimer, high sensitivity CRP, alanine aminotransferase, aspartate aminotransferase, as well as cytokines IL-6, IL-12, IL-10, Il-1 β and TNF- α . We expect that the there will be a high seroprevalence and evidence of persistent inflammation among those who are seropositive.

2. Examine ACE2 genomic factors that may influence entry of SARS-CoV-2 into cells.

The SARS-CoV-2 spike protein binds to the Angiotensin Converting Enzyme-2 receptor (ACE2)⁹⁶. In addition, ACE2 overexpression enhances viral entry and disease severity ⁹⁷. In addition, there is evidence that ACE2 genetic variants influence receptor-based association with the S protein of SARS-CoV-2. These variations could also influence the levels of ACE2 expression in various tissues. Recent work employing single-cell RNA expression profiling has shown that there is interindividual variation in ACE2 expression with some Asian patients having as much as a 5 fold difference in expression ⁹⁸. This suggests that these differences in expression may convey differential susceptibility to infection. The Cao group examined coding region variants in ACE2 as well as eQTL variants which could affect ACE2 expression. They found some variant distribution and allele frequencies that may suggest differential susceptibility to this viral infection in different populations. However, they did not specifically examine this in AAs. The genetic basis of differences in ACE2 expression levels may be a fertile area to explore in identifying those populations that are most at risk for SARS-CoV-2 infection in the United States. We will perform single nucleotide polymorphism genotyping, eQTL analysis followed by imputation and expression profiling of ACE2 among AAs. Results from ACE2 gene expression and genotype data will be deposited in dbGaP database.

3. Examine the psychosocial and socioeconomic effects of the COVID-19 pandemic among socioeconomically diverse urban AAs and whites that may influence survival.

The psychosocial and economic impact of this pandemic will be life changing for all Americans regardless of where they stand on the socioeconomic spectrum. However, it may have most significant impact on the most vulnerable with the fewest resources. We will assess the influence of the pandemic on resilience, coping, mood, food security, behavior, financial strain, medical mistrust and perceived threat.

The proposed research is relevant to examining health disparities, providing insight into important risk factors for severe disease from SARS-CoV-2 infection but will also help to ameliorate the lack of focused clinical research and the specific applications of state-of-the-art diagnostics to address persistent and significant health disparities in socially vulnerable communities.

6.1.0 Ancillary studies, sub-studies and pSITEs

6.1.1 Neuroimaging Sub-study Objectives (HANDLS Scan)

There are pronounced health disparities associated with race and socioeconomic status (SES) in various brain health endpoints including stroke, dementia, cognitive decline, and functional disability.^{99,100} Particularly potent race disparities in stroke incidence are apparent at strikingly young ages, with a four-fold increased risk of stroke mortality among 45-59 year old African Americans (AA).¹⁰¹ Efforts are needed at disentangling the respective influences of race and SES in brain health, particularly early and subtle markers of brain pathology that predict future stroke, dementia, or cognitive and functional decline. Measures of subclinical or covert cerebrovascular disease assessed by magnetic resonance imaging (MRI), including gray matter and white matter volumes and white matter microstructure, offer such proven associations.^{102,103} Identifying multilevel mediators of the relations of race and SES to subtle brain pathology is also crucial. Biomedical, behavioral, psychological, social, and environmental factors have been implicated as potential mediators of the relations of race and SES to a multitude of physical health outcomes, ^{104,105} but little is known about these pathways for brain health endpoints. ^{105,106} Recent quantitative MRI data in older adults revealed larger brain volumes, but greater white matter hyper-intensities in African Americans than whites.¹⁰⁷ The most pronounced relations of vascular disease to brain atrophy and white matter hyper-intensities were found in African Americans. MRI indices of subtle brain pathology have been associated with lower levels of cognitive and physical function and cognitive decline,^{108,109} and may mediate relations of race and SES to these endpoints.

This protocol is a sub-study linked to the ongoing HANDLS study. In a subset of 500 HANDLS participants, we will assess total and regional gray matter and white matter volumes and white matter microstructure in 500 stroke- and dementia-free HANDLS participants (250 African American, 250 white; 50% women; ages 30-64 at baseline) over the full range of socioeconomic status using quantitative MRI data, including volumetrics and diffusion tensor imaging (DTI). The data for this ancillary study will be collected at the University of Maryland School of Medicine (UMD). UMD relies on their local IRB to provide oversite. The roles and responsibilities of UMD are limited to activities related to data collection and analysis (through a data transfer agreement) for the HANDLS SCAN sub-study, under the direction of Shari Waldstein and Les Katzel, Principal Investigators. Please see appendix – Protocol for HANDLS Neuroimaging Study for specific study procedures.

We will address the following aims and hypotheses:

Specific Aim 1. Examine race- and SES-related health disparities in MRI-assessed measures predictive of future stroke, dementia, or cognitive decline, and evaluate whether these relations differ by sex and age. The primary outcome measures will include total and regional gray matter and white matter volumes quantified by voxel-based morphometry, ischemic lesion volumes, and total and regional fractional anisotropy (FA) and the apparent diffusion coefficient (ADC) estimated by DTI.

Hypothesis 1. There will be significant interactive relations of race and SES with respect to MRI indexes of gray matter and white matter volumes, ischemic lesion volumes, and white matter microstructure such that lower SES African Americans will display the most extensive brain

pathology, particularly in prefrontal regions. Moderated mediation by age and sex (i.e., that age and sex may moderate the meditational paths by which race and SES relate to brain outcomes) will be explored.

Specific Aim 2. Examine multi-level mediators of the relations of race and SES to brain MRI outcomes; potential mediators (i.e., vulnerability or resilience factors) include biomedical (e.g., cardiovascular risk factors, subclinical vascular disease, cardiovascular comorbidities), behavioral (e.g., diet, smoking, alcohol, physical activity), psychological (e.g., depression, vigilance, anger, stress, spirituality), social (e.g., social support and networks, racial discrimination), and environmental (e.g., neighborhood deprivation, access to health care) factors.

Hypothesis 2. The multi-level mediators of MRI-based measures of GM and WM will differ as a function of race and SES. For example, select psychological factors such as racial discrimination may be prominent influences in high SES African Americans (as per pilot data), whereas behavioral, social, and environmental factors may be the most prominent influences in low SES African Americans. Moderated mediation by age and sex will be explored.

Specific Aim 3. To examine whether MRI indexes of gray matter and white matter are proximal mediators of the relations of race and SES to cognitive and physical function. Hypothesis 3. Lesser white matter integrity and lesser white matter and gray matter volumes, and higher ischemic lesion volumes will be associated with lower levels of cognitive (particularly executive) function and physical function. These associations will be most pronounced among lower SES African Americans. Moderated mediation by age and sex will be explored.

6.1.2 Predictors of Personality Sub-study Objectives

There is a robust association between personality traits and consequential health outcomes¹¹⁰. Conscientiousness and Neuroticism, in particular, are essential for healthy aging. Individuals higher in Conscientiousness – the tendency to be organized and disciplined – live longer ^{111,112}, have better cardiovascular ¹¹³, metabolic ^{114,115}, immunologic ^{116,117}, respiratory ¹¹⁸, and mental ¹¹⁹ health, and are at lower risk of Alzheimer's disease ^{120,121}. Neuroticism – the tendency to experience negative emotions and vulnerability to stress – is likewise implicated in disease, including major depression ^{119,122} and coronary heart ¹²³, lung ¹²⁴, and Alzheimer's ^{121,125} disease. This robust evidence base has led to a great interest in harnessing the mechanisms and processes associated with these traits to develop more effective interventions to promote healthy aging ¹²⁶. This approach holds great promise to improve aging outcomes. Yet, little is known about how the individual's environment shapes these traits. As such, the purpose of this research is to identify how neighborhoods contribute to personality in adulthood. We also place personality in the context of a consequential health outcome – cognitive aging – to identify the dynamic interplay between personality and neighborhoods on cognitive aging.

This protocol is a sub-study linked to the main HANDLS study and is conducted out of Florida State University. Florida State University relies on their local IRB to provide oversite. The roles and responsibilities of FSU are limited to activities related to data collection and analysis (through a data transfer agreement) for the Predictors of Personality sub-study, under the

direction of Dr. Angelina Sutin. Participants will be invited to complete a personality questionnaire on-line, over the phone or by mail.

This research has two aims:

(1) To identify neighborhood antecedents of trait psychological functioning and to test biological markers as a mechanism through which neighborhood factors contribute to personality traits. We will test the *hypothesis* that greater economic and social deprivation, exposure to neighborhood crime, and greater physical disorder will be associated with the *lower* Conscientiousness and *higher* Neuroticism and that these associations will be mediated by inflammatory markers.

(2) To test whether personality traits mediate and/or moderate the relation between neighborhood factors and cognitive functioning. We will test the *hypothesis* that personality mediates the association between neighborhood factors and cognition such that neighborhood factors will inhibit self- and emotion-regulation traits, which contributes to greater cognitive decline in older adulthood. We will also test the *hypothesis* that higher Conscientiousness and lower Neuroticism buffer the harmful effect of neighborhood risk on cognitive aging.

The POP study will be conducted out of FSU. Participants will be informed about the study on personality and how to participate. Informed consent will be obtained from willing participants following guidelines and regulations set forth by FSU and their IRB. The questionnaire will consist of personality measures and questions about their neighborhood. Participants will be compensated with a retail gift card (\$40), which will be provided electronically when possible, or mailed to them after receipt of the completed questionnaire.

All data for this ancillary study will be collected at the Florida State University (FSU). FSU relies on their local IRB to provide oversite. The roles and responsibilities of FSU are limited to activities related to data collection and analysis (through a data transfer agreement) for the HANDLS POP sub-study, under the direction of Angelina Sutin, PhD, Principal Investigator.

6.1.3 Pennsylvania State University *pSITE* Roles and Responsibilities

The Pennsylvania State University (PSU), institution of Dr. Alyssa Gamaldo, extramural *HANDLS Sleep Study* Principal Investigator and NIH special volunteer will collaborate with the NIA HANDLS study team, in tracking, locating, and screening participants for the PSU Sleep Study and conducting collaborative analyses. PSU will assist in mailing/tracking letters inviting and screening participants from the HANDLS main study to participate in the HANDLS Sleep Study. The activities of PSU on the NIA HANDLS Study (NIH IRB#: 09AGN248) will be overseen by the NIH IRB through a reliance agreement. The HANDLS Sleep Study (PI: Alyssa Gamaldo/NIH IRB#: 001047; NIA PI: Michele Evans) was approved under the Westat IRB. NIA/PSU researcher's activities on the HANDLS Sleep Study will be overseen by the Westat IRB through a reliance agreement. PSU will be carrying out the research activities at PSU in PSU facilities and/or on PSU monitored technological equipment.

PSU's primary role in the HANDLS study is to assist the NIA HANDLS study team with tracking and screening participants for a separate study. They will perform the following activities in collaboration with the NIA HANDLS Team:

- Determining eligibility for the study (confirming they are on the list of participants with actigraphy data and meet the criteria outlined in the sleep protocol).
- Mailing invitation letters informing HANDLS participants about the Sleep Study. The letter has been reviewed and approved by the NIH IRB in its capacity as the reviewing IRB for NIH Protocol 09AGN248.
- Screening subjects includes taking calls from participants who respond to the invitation letter asking about the Sleep Study and calling participants who have not responded to the initial mailing to determine if they received the letter or if their address needs to be updated.
- Updating contact information from subjects (for example if their address has changed the main HANDLS record will be updated).
- receiving data to conduct analysis to be used in research publications or presentations or working with coded data/ specimens and will have access to the code key. Identifiable data will be shared with subject consent.

7.0.0 Expected Risks and Benefits

There is very little risk to participants in this observational study. The exposure to low dose radiation from the analysis of bone density and body composition by the densitometer and the risks associated with having blood drawn are the minimal risks.

The potential benefits to the participants include access to a full medical evaluation including screening for pathology in which early detection is advantageous. If the study doctor discovers any condition or problem, the information is provided to the participant immediately and their primary care doctor, with their permission. If the participant does not have a physician, efforts will be made to refer them for care. Participants will be reimbursed for time and inconvenience.

The potential benefits to society relate to improvement of overall health in a vulnerable population that currently bears a disproportionate burden of disease and disability in this country. Healthy People 2010, the nation's disease prevention agenda, have defined two national goals to reduce preventable threats to the nation's health.¹²⁷ The first is to increase the quality and years of healthy life and the second is to eliminate health disparities. However, in order to achieve this second goal it is critical to develop research initiatives that provide new insights into the relationship between psychosocial factors and health status by (1) incorporating biological measures into large scale epidemiologic health and survey research projects and (2) the development and inclusion of a diverse panel of biomarkers or biologic measures that evaluate biologic pathways that may be involved in the causal relationship between SES and health.¹²⁸ This is what HANDLS attempts to accomplish. If successful, HANDLS will provide unique information that will hopefully uncover findings that will provide a basis for the development of appropriate prevention and intervention strategies to reduce health disparities.

8.0.0 Eligibility

In this study, we are examining age related disorders in a target population of African Americans and whites in a representative sample of Baltimore City residents.

Inclusion criteria: (1) Verified HANDLS participants (age 30-64 at baseline recruitment); (2) able to give informed consent (or has a legal designee); and, (3) must have valid picture identification.

Exclusion criteria: (1) Pregnancy (for the MRV examination visit and the HANDLS Scan substudy a urine pregnancy test is performed with women of child bearing potential during the medical screening prior to any testing or procedures. If positive, participant will not be eligible for the MRV examination visit until they are no longer pregnant. Participants with a positive pregnancy test will be invited to return for the MRV examination visit and/or the HANDLS Scan once pregnancy is resolved (pregnancy testing is repeated at each encounter, if indicated). The home visit protocol does not pose increased risk so pregnancy status is not required or obtained); and (2) Current cancer chemotherapy or radiation therapy.

9.0.0 Subject Enrollment


Plan to re-contact participants for Wave 7. The HANDLS study has recruited a representative sample of 3720 whites and African Americans between 30 and 64 years old from 13 neighborhoods in Baltimore city in both low and high socioeconomic strata as a fixed cohort following the overall design. We have used several methods to remain in contact with our participants since they initially enrolled in HANDLS. Specific examples include sending regular mailings such as newsletters, holiday and birthday cards to the addresses we have on file, participation in the wave 2 interim study, mailing study updates and reminders with change of address cards, and periodic reviews of the Baltimore city judicial system public records and the National Death Index database. While this does allow us to remain in contact with many of our participants, there still exists a sub-set of participants for whom traditional methods will not be successful.

For Wave 7 we employ a tracing and tracking specialist whose primary responsibility is to focus on conducting investigative fieldwork and extensive tracing & tracking procedures to locate missing participants. This requires (a) physically driving through all identified HANDLS study neighborhoods in Baltimore City to previously known addresses for missing participants, communicating with current residents (and or neighbors) of identified households to assist in locating participants; (b) contacting participant's family or friends identified by the participant as persons to be reached if participant cannot be located (c) using search engines on the internet, Baltimore City judicial system public records, National Death Index, Division of Vital Records, and similar methods to locate current residence or to verify status of missing participants; and, (d) other tracing and tracking methods developed over time and with experience.

Including this strategy will allow us to make every possible effort to locate as many of our participants as possible. It is particularly crucial in this first follow-up re-examination phase of the study.

10.0.0 Study Design and Procedures

The HANDLS study is an interdisciplinary, prospective epidemiologic longitudinal study examining the influences and interaction of race and SES on the development of cardiovascular and cerebrovascular health disparities among minority and lower SES subgroups.








Figure 3. HANDLS baseline accrual

The baseline HANDLS sample consists of 3720 community-dwelling African American and white adults aged 30-64. Participants were drawn from 13 neighborhoods (groups of contiguous census tracts) in Baltimore City, sampling representatively across a wide range of socioeconomic and income circumstances. The heuristic study design is a factorial cross of four factors: age, sex, race, and SES with approximately equal numbers of subjects per "cell" (Figure 2). HANDLS is planned as a 20-year longitudinal study of the 3720 individuals accrued (Figure 3). Using our mobile medical research vehicles, we are revisiting each census tract for 2-3 months over the next 3 years.

The 13 neighborhoods identified were selected because they were likely to yield representative distributions of individuals between 30 and 64 years old who are African Americans and whites, men and women, and lower and higher SES.

Study sample. The study recruited an area probability sample of whites and African Americans between 30 and 64 years old from 13 neighborhoods in Baltimore City in both low and high socioeconomic strata as a fixed cohort following the overall design. By collecting a baseline assessment and 5 follow-up triennial assessments over approximately 20 years, there will be sufficient power (>.80) with 30 participants per group (race by SES by sex by age group) remaining after 20 years. There will also be sufficient power (>.80) to compare rates of change among groups after the baseline assessment.

Procedures. The primary study data for wave 7 is collected during the MRV examination or home visit, a telecommunications visit, or a combination of an in-person examination visit and a telecommunications visit. These data include an interim medical history and physical examination since the baseline examination; cognitive and sensory evaluation; assessment of health literacy, cardiovascular function: electrocardiogram, assessments of muscle strength, lean body mass and bone density; laboratory measurements (blood and urine chemistries, hematology, biomaterials for genetic studies) and, an audio-administered questionnaire. For those participants who have difficulty ambulating independently, we recommend they complete the HANDLS home visit for wave 7 (see home visit table of procedures below). Westat staff

will collect the home visit data. Westat relies on the IRB of record for the National Institute on Aging to provide IRB oversight through an IRB reliance agreement. The roles and responsibilities of Westat are limited exclusively to activities related to data collection for the HANDLS Home Visit Program (HHVP), under the direction of Catherine Torres, Principal Investigator.

For the telecommunications/virtual visit participants will complete the informed consent process, the audio-assisted questionnaire and interim medical history using the Zoom.gov platform. The procedure for conducting the virtual visit has been reviewed and approved by the NIA Information Systems Security Officer. Providing this option for participants will decrease the time of the in-person examiniation visit on the mobile Medical Research Vehicles, thereby reducing participant burden and in-person contact.

A selected subset of participants is invited to participate in the optional studies, the neuroimaging sub-study and the predictors of personality sub-study. We conduct the neuroimaging study at University of Maryland School of Medicine and the predictors of personality study will be conducted out of Florida State University.

Results. Participants receive a copy of their clinical laboratory findings within 2 weeks of their examination visit (home visit or MRV). If a result is critical or needs further evaluation, the HANDLS clinician will contact the participant by telephone as soon as possible following the notification (within 24-48 hours), and will send a copy of the result to the participant the same day. If the participant agrees and provides consent to release information, a copy of the results are also sent to the participant's physician. If the participant does not have a physician the HANDLS nurse or social worker will facilitate a referral for follow-up care. The HANDLS clinician is available for further consultation with the participant and or their physician to provide additional information and or to facilitate follow-up care.

Approximately 8-12 weeks following their visit participants receive a Participant Report Packet with a copy of the results from their blood, urine tests, COVID testing, EKG, fundus photography and DXA Scan. If the participant agrees and provides consent to release information, a copy of the results are sent to the participant's physician.

If the participant agrees to COVID testing, they will be given results of the BD Veritor System for rapid detection of SARS-CoV-2 or the Flow*flex* COVID-19 Antigen Test during their examination visit. They will receive the results of both the Nasopharyngeal Mucosa Swab and the antibody test within 24 hours of the study clinician receiving the report. The tests will be performed by Quest Diagnostics in Baltimore, MD, a CLIA certified laboratory. Specifically, the tests to be performed are the Hologic Panther Fusion and the Abbott Architect both of which are approved by the EUA. Positive *Nasopharnygeal Swab for SARS-CoV-2* test results will be reported to the Department of Health and Mental Hygiene using DHMH form 1140 within 24 hours of receiving a positive test report. There are two available options for reporting a positive result. The test report could either be faxed to the Baltimore City Health Department at 410-625-0688 or it will be mailed to DHMH in a sealed envelope marked "confidential." Addressed to; Commissioner of Health Baltimore City 1001 East. Fayette Street Baltimore MD 21202 Ph. 410-396-4436.

HANDLS Scan reports of incidental findings are received from the University of Maryland within one week of the scan. If a result is critical or needs further evaluation, the HANDLS clinician will contact the participant by telephone as soon as possible following the notification (within 24-48 hours), and will send a copy of the result to the participant via certified US mail the same day. If the participant agrees and provides consent to release information, a copy of the results is also sent to the participant's physician. If the participant does not have a physician the HANDLS nurse or social worker will facilitate a referral for follow-up care. The HANDLS clinician is available for further consultation with the participant and or the physician to provide additional information and or to facilitate follow-up care.

Home Visit

| Measure or Procedure | Estimated Timing |
|---|------------------|
| **Consent (completed by phone or in-person) | 20 minutes |
| BD Veritor Sys for rapid detection of SARS-CoV-2 or | |
| the Flow <i>flex</i> COVID-19 Antigen Home Test | 20 minutes |
| Specimen Collection*, Vitals and EKG | 45 minutes |
| Cognition & sensory testing (smell) | 60 minutes |
| **Interim Medical History | 30 minutes |
| Interim Physical Exam | 45 minutes |
| Skin & toenail sample collection | 10 minutes |
| Hand Grip | 10 minutes |
| **Questionnaires | 15 minutes |
| Health Literacy | 10 minutes |
| *Includes Nasopharyngeal Mucosa Swab | |

Medical Research Vehicle Examination

| Measure or Procedure | Estimated Timing |
|---|------------------|
| **Consent | 20 minutes |
| BD Veritor Sys for rapid detection of SARS-CoV-2 or | |
| the Flow <i>flex</i> COVID-19 Antigen Home Test | 20 minutes |
| Specimen Collection (Urine, Blood, Saliva & | |
| Nasopharyngeal Mucosa Swab) | 20 minutes |
| Height & weight | 05 minutes |
| Interim Physical Exam | 30 minutes |
| **Interim Medical History | 20 minutes |
| Skin & toenail sample collection | 10 minutes |

| Cognition & Sensory Testing | 60 minutes |
|--------------------------------------|------------|
| Physical Performance | 15 minutes |
| EKG | 10 minutes |
| **Questionnaire Section | 50 minutes |
| Health Literacy | 10 minutes |
| Body Composition & Bone Densitometry | 05 minutes |

****Includes procedures that may be administered by telecommunication**

Neuroimaging Sub-study

| Measure or Procedure | Estimated Duration | Location |
|----------------------|-----------------------|----------|
| Neuroimaging Study | 90 minutes | UMB |

Predictors of Personality Sub-study

| Measure or Procedure | Estimate | Location |
|------------------------|--------------|----------|
| Personality Questionna | ire 60 minut | es FSU |

11.0.0 Procedure Description

Telehealth/virtual research visits

Participants will be invited to participate in a virtual teleconference using a government issued zoom account. The visit is designed to obtain informed consent and to conduct the ACASI questionnaire and interim medical history prior to the participant coming to the MRVs for their follow-up examination visit. The informed consent process for the virtual visit is described on

page 35 of this protocol and the procedures (audio-administered questionnaire and the interim medical history) are described below.

Collection and Analysis of Biomaterials

Blood and Urine Fasting blood samples for clinical tests, banking plasma, serum, and DNA. As a part of the medical evaluation, blood tests are performed to look for anemia and other blood disorders, diabetes mellitus, thyroid disease, hepatitis, prostate disease, HIV disease, kidney disease and COVID infection. We are also using some blood samples to study genes that may play a role in age-related diseases like Alzheimer's disease, heart failure, high blood pressure, and cancer. The total amount of blood drawn from each participant is about 87.2 milliliters (~6 tablespoons). A random urine sample is collected for urinalysis, measurement of microalbuminuria, and storage.

Risks. There are some risks from having blood drawn. There is a risk of an infection from the needle puncture. There is also a risk of a black and blue mark, and the participant may feel faint. It is common to have a small black and blue mark, but it disappears after a day or so. Some people may begin to perspire or feel nauseated. These risks are very small. Our medical staff is well trained and has drawn blood many times. There is no risk for urine collection.

Buccal cell collection. As part of the medical evaluation buccal mucosa cells are collected from saliva samples using the Genotek Oragene DNA self-collection kit from each consenting participant. Participants are asked to spit into a DNA collection system (a small sample cup) to collect buccal mucosal cells. The extracted DNA will be used for epigenetic analysis as well as human mRNA expression profiling.

Risks. This is a completely non-invasive self-collection system. There are no known physical risks.

Alternative buccal cell collection method. The Whatman FTA collection system will be used as a back-up buccal cell collection method. This system collects buccal cells using a foam tipped applicator which is placed into the mouth and rubbed on the inside of both cheeks for 30 seconds by the participant. The sample obtained is then transferred to the Indicating FTA cards. The extracted DNA will be used for epigenetic analysis.

Risks. Buccal mucosa smear risks include irritation of the inside of the cheek and/or gum line by the foam tipped swab used to collect cells and saliva.

Toenail clipping for environmental exposure assessment. The purpose of this test is to examine possible exposure to chemicals and/or toxins in the environment. We want to assess whether environmental exposure to certain chemicals and/or toxins contribute to the development of age-related diseases in our participants. We will clip a very small amount of nail from each of toes of both feet using a single use toenail clipper.

Risks. Cutting too close to the nail bed may result in blood loss (minimal) and risk of infection.

Skin swab. We want to study the interaction between microbiome and the immune system to examine if there is a relationship to poor wound healing and/or the development of age-related

diseases. Skin bacteria will be collected using a sterile cotton swab brushed across the volar aspect of the dominant arm to examine skin microbiota.

Risks. None

Nasopharnygeal Swab for SARS-CoV-2. This test is to collect cells from the nasal passage to test for the COVID-19 virus. We will use a special nose swab to collect these cells from inside the nose. Participants will receive a report with their test results.

Risks: mild discomfort, temporary irritation of nose canal

Exclusions: recent nose trauma or surgery

BD Veritor System for rapid detection of SARS-CoV-2. This test is to collect cells from the breathing tract in the back of the throat to test for the COVID-19 virus. We will use a special nose swab to collect these cells from inside the nose. Participants will receive test results within 20 minutes of sample collection.

Alternative to the *BD Veritor System for rapid detection of SARS-CoV-2*. The Flow*flex* COVID-19 Antigen Home Test wll be administered if the BD veritor system is not available for the rapid detection of SARS-CoV-2. This test is to collect cells from inside the nasal passages to test for the COVID-19 virus. We will use a special nose swab to collect these cells from inside the nose. Participants will receive test results within 20 minutes of sample collection.

Risks: mild discomfort, temporary irritation of nose canal

Exclusions: recent nose trauma or surgery

Anthropometrics. We measure the height and weight and knee height of each participant.

Risks. None.

Medical history and physical examination. A physician or nurse practitioner performs an interim physical examination and medical history. The purpose of the physical examination and medical history is to document as unambiguously as possible any diagnosable conditions, to record medications and their frequencies and dosages, and to assess disabilities that might limit independent functional activities, that have developed or occurred since their last examination on the MRVs. In addition, we will examine subjects to ensure that they do not meet exclusionary criteria for any subsequent tests such as the DXA.

Risks. None.

Cognitive testing. We administer The Trail Making Test as a measure of executive function and the Mini-Mental State Examination¹²⁹ to screen for dementia. We assess symptoms of depression using the Center for Epidemiologic Studies Depression inventory (CES-D)¹³⁰. These tests are given in a private, quiet room with an experienced psychometric technician.

Risks. None.

Sensory Testing

Sniffin' Sticks Test of Olfactory Function. The purpose of the Sniffin' Sticks test is to see if we can find problems with the ability to identify smells. Sometimes problems with smell can be related to medical, psychological or brain conditions.

Odor identification with *Sniffin' Sticks* is performed by holding an uncapped canister that resembles a marker pen 2 cm from participants' noses while asking them to sniff the odor.

Brief Smell Identification Test (BSIT). The BSIT is also used to detect smell deficits which may be related to medical, psychological, or neurological conditions. The BSIT consists of 1 booklet with 12 scratch and sniff items per book (1 odorant per page; 12 questions total). To take this test, a participant scratches the odorant label on the page with a pencil, sniffs it, and identifies the odor. Above each label is a multiple-choice question asking the participant to identify the odor. The BSIT will be used as an alternative to the *Sniffin' Sticks* when physical distance limits are imposed.

Risks. There are no known risks associated with these tests. Participants may find some odors unpleasant but the smell will go away quickly.

Visual Acuity and Fundus Photography. The purpose of this tests is to learn more about Agerelated Macular Degeneration (AMD), a condition that can develop as we age. We will also test visual acuity.

Fundus Photography. Photographs will be taken of the back part of the eye (fundus) with a special camera. The participant will see some flashing lights.

Optical Coherence Tomography (OCT). These tests use a machine to examine the thickness of the different layers of the eyes and to evaluate for any changes in the normal structures in the retina. OCT will be repeated during the study to determine changes in the thickness of the different retinal layers and for changes in the structures of the retina. Participants will see a brief flash of light during the test.

Risks. The taking of photographs is not associated with any risk; however, the bright lights may cause temporary discomfort.

Visual Acuity Test. The study team will test participant's vision. Visual acuity (reading letters on an eye chart) will be measured using a machine called a refractometer.

Risks. These tests have no risk and will not cause discomfort. Participants will get a report of results.

Physical Performance Measures

The purpose of this performance battery is to estimate hand grip strength which has been associated with mortality and lower-extremity function and in this wave to carefully assess loss

of functional capacity among participants. Use of these selected elements of the Short Physical Performance Battery and the hand grip will permit comparison to other nationally representative cohorts.¹³¹

Hand Grip Strength test. Handgrip strength in both hands, measured using an adjustable, handheld, hydraulic grip strength dynamometer, is used as an overall assessment of physical strength and skeletal muscle function. Repeated measurement of grip strength over the follow-up visits will permit an estimate of strength loss over time. Grip strength is a commonly used indicator of health status and physical frailty and mid-life grip strength has been shown to be a strong predictor of early mortality.

The examination is done with the participant in the sitting position with the arm to be tested resting on the table and the elbow held at approximately a right angle. The dynamometer is held in the hand to be tested and is resting on a mouse pad. The participant is instructed to grip the two bars of the dynamometer in their hand, and to slowly squeeze the bars as hard as they can. The test is repeated on the other hand. This test is performed 3 times on each hand.

Exclusions. Participants who have had fusion, arthroplasty, tendon repair, synovectomy, or other related surgery of the upper extremity in the past 3 months will not be tested on the affected hand.

Sit-to-stand test. A commonly used performance-based test of physical function, the sit-to-stand test (also termed repeated chair stands), is used to assess functional status at study inception and to tract loss of functional capacity over time. Using a standard armless chair placed securely against a wall, the participant is first instructed to rise from the chair without using arms and return to a seated position. If this is done successfully, the participant is then asked to repeat that movement 10 times. Performance, both whether 10 stands are completed and time to perform 5 or 10 stands has been strongly associated with onset of functional limitation, physical disability, institutionalization, and mortality.

Exclusions. There are no formal exclusions from attempting the single chair stand; inability to rise from a chair without using arms excludes participants from doing repeated chair stands.

Tests of Standing Balance

Side-by-side stand. The side-by-side stand test should be performed with the participant standing a little less than an arm's length from a wall to provide an additional source of support if a loss of balance does occur. This test requires the participant to stand with feet side by side for 10 seconds.

Semi-Tandem Stand. The Semi-Tandem stand test should be performed with the participant standing a little less than an arm's length from a wall to provide an additional source of support if a loss of balance does occur. This test requires the participant to stand with the side of the heel of one foot touching the big toe of the other foot for about 30 seconds.

Tandem Stand. The Tandem stand test should be performed with the participant standing a little less than an arm's length from a wall to provide an additional source of support if a loss of

balance does occur. This test required the participant to stand with the heel of one foot in front of and touching the toes of the other foot for 30 seconds.

Single leg stand. The single leg stand test should be performed with the participant standing a little less than an arm's length from a wall to provide an additional source of support if a loss of balance does occur. This test requires the participant to stand on one leg with the other leg flexed at the knee and held about two inches from the floor. The participant is asked to hold the position for as long as they can, up to 30 seconds. The single leg stand has been found to be a sensitive test of standing balance for middle age and older adults and has been used in numerous epidemiologic studies of well elderly without mishap.^{131,132}

Risks. There are very minimal risks associated with the Physical Performance Measures. The only risks are that there is a slight risk of falling and the participant may feel tired after these tests.

Cardiovascular Function

Resting electrocardiogram (EKG). We place electrodes on the participant's skin to record their heartbeats. By looking at the electrical pulse of their heart we examine the heart rate and rhythm, and check if they have had a heart attack.

Risks. None.

Audio-administered questionnaires. We assess risk of poor mental health, memory concerns, joint pain, stiffness, and joint physical function and questions about food security, the COVID Pandemic, smoking behaviors, happiness, experiences with gun violence and income with an audio-administered questionnaire. Assistance is provided to the participants, if for example they have trouble seeing or reading the questions or are uncomfortable with using a computer.

Risks. None.

Health literacy. To assess health literacy in Wave 7, we will use a shortened version of the Rapid Estimate of Adult Literacy in medicine (REALM). The REALM assesses reading level through scoring pronunciation of a list of health care related terms by participants. It correlates with other measures of reading literacy and health literacy.

Risks. None.

Bone density and body composition. We perform dual energy X-ray absorptiometry (DXA) on total body, lumbar spine, the hip and the Instant Vertebral Assessment (IVA) using the Hologic Horizon A (Hologic Inc., Marlboro, MA). DXA delivers a small amount of radiation through an X-ray source while you lay on the scanner bed. Site-specific scans of the lumbar spine and right hip provide information on bone area (cm²), and bone mineral density (g/cm²). Total body scan measures both body composition and bone mineral density, including bone mineral content (g), bone area (cm²), bone mineral density (g/cm²), total body tissue (g), fat mass (g), lean mass (g), lean mass plus bone mineral content (g), and percent total fat (%). The IVA provides an assessment of vertebral fractures. Results of the total body scan are presented for the whole body as well as for the arms, legs, trunk, head, pelvis, and spine.

Exclusions. DXA studies are not administered to pregnant women or individuals weighing greater than 450 pounds due to the densitometer's limitations.

Risks. The NIH Radiation Safety Committee has reviewed the use of radiation in this research study and has determined this use as involving minimal risk and necessary to obtain the research information desired. Although each organ receives a different dose, the amount of radiation exposure participants receive from these procedures is equal to a uniform whole-body exposure of less than 1 millirem. This calculated value is known as the "effective dose" and is used to relate the dose received by each organ to a single value. The amount of radiation received in this study is within the dose guideline established by the NIH Radiation Safety Committee for research subjects. The guideline is an effective dose of 5 rem (or 5,000 mrem) received per year.

The NIH Radiation Safety Branch monitors equipment and technique used in this study.

12.0.0 Collection and Storing of Human Sample Specimens and Data

Intended use of the samples, specimens, and data. Samples and data collected under this protocol may be used to study the differential influences of race and socioeconomic status on health in an urban population. Genetic testing will be performed.

Labeling of stored samples. Participants' stored samples will be labeled with HANDLS identification numbers that only the study team can link to participants. Any identifying information about participants will be kept confidential to the extent permitted by law.

How samples, specimens, and data will be tracked? Samples are tracked using the NIA Biological Sample Inventory system following NIH guidelines.

Storage and release of samples. Samples of the participant's blood are kept in a research laboratory at the National Institutes of Aging, NIH or one of our contract facilities. The subject's samples are tested immediately, or they may be frozen and used later. Informed consent allows subjects to determine future use and use for genomic projects. The subject's samples are stored with a confidential code. Samples may be kept until no cells remain or until the investigators decide to destroy them. If the participant gives us permission some samples are released to other doctors and scientists who are not associated with this institute. The Clinical Director and the Principal Investigators on this protocol will decide which researchers may receive samples. The subject's samples may be used in their research only if the research has been approved by an Institutional Review Board (IRB) and is related to the original research questions association with this protocol or for other research purposes as indicated below. Access to the samples will be limited by storing samples in a locked room.

What will happen to the samples, specimens, and data at the completion of the protocol? The stored material will be used only for research and will not be sold. At the completion of the protocol, samples and data will either be destroyed, or after IRB approval, transferred to another existing protocol.

What circumstances would prompt the PI to report to the IRB loss or destruction of samples, specimens, or data? We will report any loss of samples (e.g., freezer malfunction to the IRB

according to NIA protocol violation policy. In addition, we will report to the IRB any loss of unanticipated destruction of samples or data.

Participants may decide at any point not to have to have their samples stored. In this case, the Principal Investigator will destroy all known remaining samples and report what was done to the participant and the IRB. This decision may not affect participants' status in this protocol or any other protocols at NIH.

13.0.0 Data Collection and Management Procedures

HANDLS data are collected electronically or manually on the MRVs, over the telephone and in participant's homes. Data are kept in medical charts in locked file cabinets. Electronic data is kept on password-protected computers. All clinical research forms are filed in locked file cabinets. These materials are kept within a locked medical record room. Access to all study data is limited to HANDLS staff and investigators. Data are coded and entered by ID number only. Collaborators receive ID numbers only. No other identifying information is provided with the data unless there is a data use or materials transfer agreement in place, consent has been obtained from the HANDLS participant and the collaborators have obtained required IRB approval.

Data analysis. The study employs a standard statistic software package depending on the independent and dependent variables being analyzed. Data analyses include logistic regression and mixed effects modeling.

Data sharing agreement. Data generated by the HANDLS study is available through several mechanisms including publications, presentation of results at national scientific meetings, and via a proposal review mechanism routed through the HANDLS principal and co-investigators working group.

The HANDLS web site (http://handls.nih.gov) contains a data dictionary for each of the study domains outlining available data sets. This website also describes the proposal submission process for investigators who would like to use HANDLS data or biomaterials. Proposers are required to submit an electronic HANDLS concept sheet detailing the hypotheses and specific aims of the proposals as well as the required data sets and/or biomaterials. These proposals are reviewed by the HANDLS Working Group. Meritorious proposals are assigned a HANDLS Investigator to serve as liaison and collaborator working with the successful proposer facilitating the completion of the NIA and NIH data transfer or material transfer agreements required by federal regulations and to access and use the data set (s) or biomaterials required for the approved proposal. Proposals not completed and submitted for publication within the time frame stipulated in the proposal will be re-negotiated or terminated.

Data safety and monitoring. No data or safety monitoring board is required. The Principal Investigator will monitor and evaluate the progress of the study, including periodic assessment of data quality and timeliness, participant recruitment, accrual and retention, participant risk versus benefit, performance of contractors and other factors that can affect study outcome. This monitoring will also consider factors external to the study when interpreting the data, such as scientific or therapeutic developments that may have an impact on the safety of the participants or the ethics of the study.

14.0.0 Quality Control

All data for the HANDLS study is collected by following detailed Standard Operating Procedures (SOPs) as outlined in the HANDLS Operations Manual. The majority of data is collected electronically, in real time, and is monitored at regular intervals for accuracy and adherence to the protocol by HANDLS computer programmers and information technology specialists. Manually collected data are stored in the research medical record and are reviewed for accuracy and completion daily by the HANDLS Medical Records Specialist. The HANDLS Clinical Study Manager selects medical records at random for monthly audits.

15.0.0 Statistical Considerations

Power analysis. Initial estimates based on the 2000 census data indicate that we needed to visit approximately 35% of the households in each census tract to collect the required 333 individuals. The initial sample of 3,500-4,000 participants is based on power analyses and assumptions about attrition over 20 years. For a power of 80% (the likelihood of finding an effect if it is really present), we can identify moderate effects (magnitude of the differences between groups) for various outcomes with as few as 30 participants per group at the end of the study. Working backwards by assuming 20% attrition after the baseline assessment and 15% attrition between subsequent assessments, we need approximately 3,500-4,000 participants at baseline to yield 1,680 after 20 years.

Data analyses. The study employs standard statistical software depending on the independent and dependent variables being analyzed. Data analyses include parametric and nonparametric statistics for cross-sectional comparisons applying logistic regression and mixed effects modeling as appropriate for the data. Longitudinal analyses will typically require either mixed-effects models, survival analyses, or proportional hazards depending on the data and specific outcome under study.

16.0.0 Regulatory Requirements

16.1.0 Informed Consent

Wave 7. Informed Consent for Wave 7 will be obtained in-person at the MRVs, over telephone/video conference, or in the participant's home. Among the preparations for their examinations on the medical research vehicles and the home visit, participants are provided copies of the informed consent documents and are asked to read them. Participants are then instructed to view a consent video about the HANDLS study that explains the purpose of the study and all procedures they have previously reviewed in the informed consent documents. The HANDLS study consenter then reviews each document with participants a final time, page by page stopping to ask if they have any questions to ensure the participant has a clear understanding of the study, the degree of risk, potential benefits, and alternatives and then provides the participant with an opportunity to ask any further questions and to consider their decision to participate in this next wave of the HANDLS study. If participants agree to take part, signatures will be obtained using an IRB approved hard copy of the informed consent document or electronically using a PC tablet. HANDLS staff provides participants with printed copies for

their records and a copy is placed in the research medical record. HANDLS staff sends participants copies of all informed consent documents with the results from their examinations.

Participants being consented over the telephone or videoconference will be mailed a consent form at least 7 days prior to their telecommunications appointment. When the consenter makes the initial appointment they will encourage participants to read through the consent document prior to their scheduled appointment. Participants will be reminded that they may consult with family and friends and their doctor if they like, and to consider carefully whether they want to participate in the next examination visit for HANDLS. At the beginning of the telephone or video conference, participants will confirm they are in a private space with minimal disruption to conduct the interview and will also will confirm they have their hard copy of the consent form and that they have had an opportunity to read it. If the participant has not reviewed the hard copy consent they will be provided time to do so. If they did not receive it or have misplaced it, the consenter will offer the following options: (1) read the form to the participant or (2) view it on their screen, if video equipt, or (3) reschedule the appointment and resend the informed consent document so they have time to review the material before the meeting. When the participant is ready to begin, they will confirm they have had time to review the hard copy consent form and will view a consent video about the HANDLS study that explains the purpose of the study and all procedures they have previously reviewed in the informed consent document. The HANDLS study consenter then reviews the consent document with participant a final time, page by page stopping to ask if they have any questions to ensure the participant has a clear understanding of the study, the degree of risk, potential benefits, and alternatives. The consenter then provides the participant with an opportunity to ask any further questions and to consider their decision to participate in this next wave of the HANDLS study. The telephone/video consent procedure will be witnessed by another HANDLS staff person (permission to include the witness will occur at the beginning of the call), who will ask the participant the following questions:

- 1. Is there anything you would like {insert consenter's name} to repeat?
- 2. Have you understood everything {insert consenter's name} has told you?
- 3. Do you have any questions?
- 4. Do you agree to participate?

If the participant agrees to participate, they will be encouraged to keep their copy of the consent form for future reference and their consent will be noted in the electronic medical record (MRVWEB).

Request for waiver of documentation of informed consent for telecommunications visit prior to in-person examination visit – We request a waiver of written documentation of consent for the telecommunications visit as the activities involve procedures for which consent is not normally required outside the research context and present only minimal risks to the participants.

Wave 7 - optional studies. Informed consent for the Neuroimaging Study will take place at the UMD following guidelines set forth by their IRB. Informed consent for the Predictors of

Personality sub-study will take place at Florida State University following guidelines set forth by their IRB.

Durable Power of Attorney for Health Care Decision Making. During wave 4 participants were asked to designate a heath care agent by completing NIH form 200-(10-00) Durable Power of Attorney for Health Care Decision Making. Participants were informed that the designee will be able to make decisions regarding their participation in HANDLS (and any clinical care related to their participation), in the event they are unable to make their own decisions due to diminished capacity. A copy of the form will be mailed to the person they name and participants will be encouraged to discuss their known desires and values with the designee, their personal physician and their family. During W5 if a participant no longer has decisional capacity, HANDLS staff will consider calling the participant's health care designee to discuss the feasibility and consent to participate in W5.

16.2.0 Compensation

The amount of payment to research volunteers is guided by the National Institutes of Health policies. In general, participants are not paid for taking part in research studies at the National Institutes of Health. Reimbursement of travel and subsistence will be offered consistent with NIH guidelines.

Participants may be reimbursed up to a total of \$390 for participating in the HANDLS - wave 7 study, including the sub-studies. They may be paid up to \$300 for participating in the MRV visit or up to \$240.00 for the Home Visit. If they participate in the Neuroimaging study at the University of Maryland they will be compensated an additional \$50.00, and if they participate in the Predictors of Personality sub-study they will receive an additional \$40.00 retail gift card.

If a participant is unable to complete all the tests they may receive a portion of that payment. They will receive payment in the form of an ATM debit card at the end of each phase. In most cases, the ATM card will be activated by the end of the study visit day. The participant will be instructed to take the card to an ATM machine of their choosing to withdraw payment. Written instructions regarding how to access payments will be provided. Occasionally participants are not able to complete all testing in one visit to the MRVs or some tests require repeating if there are questionable or abnormal results. We would like to be able to offer additional compensation for time and travel to return to the MRVs for return visits. The amount of compensation will vary between \$40.00 and \$100.00 depending on the length of time spent on the MRVs. We anticipate the return visits to be between 1-4 hours. This would include participants who never had a baseline evaluation.

16.3.0 Subject Confidentiality

HANDLS participants' confidentiality will be maintained by informing them of the following:

When results of an NIH research study are reported in medical journals or at scientific meetings, the participants will not be named and/or identified. In most cases, the NIH will not release any information about participant's research involvement without their written permission. However, if they sign a release of information form, for example for an insurance company, the HANDLS Medical Records Specialist will give the insurance company information from the medical

records. Participants are informed this information might affect (either favorably or unfavorably) the willingness of the insurance company to sell them insurance.

The participants are informed that the Privacy Act protects the confidentiality of their medical record. However, the Act allows release of some information from the medical record without permission, for example, if the Food and Drug Administration (FDA), members of Congress, law enforcement officials, or authorized hospital accreditation organizations, require it.

To help us protect privacy, we have obtained a Department of Health and Human Services Certificate of Confidentiality issued by the National Institutes of Health. With this certificate the researchers cannot be forced to disclose information that may identify participants, even by court subpoena, in any federal, state, or local civil, criminal, administrative, legislative or other proceedings. The researchers will use the certificate to resist any demands for information that would identify them, except as explained below. The Certificate cannot be used to resist a demand for information from personnel of the U.S. Department of Health and Human Services that is used for auditing or program evaluation or for information that must be disclosed in order to meet federal regulations. A Certificate of Confidentiality does not prevent participants or a member of their family from voluntarily releasing information about themselves or their involvement in this research. If an insurer, employer, or other person obtains written consent to receive research information, then the researcher may not use the Certificate to withhold that information. The Certificate of Confidentiality does not prevent the researchers from disclosing voluntarily, without participant's consent, information that would identify them as a participant in the research project under the following conditions: It does not apply to state requirements to report certain communicable diseases. In addition, the study clinician may be required to report certain cases of abuse, neglect, or suicidal or homicidal intent to the appropriate authorities.

Information regarding who will have access to the data and use of personally identifiable data or private health information (PHI) are described in further detail in sections 14.0.0 (data collection and management procedures) of this protocol.

17.0.0 Participant Safety, Adverse Events & Problem Reporting

17.1.0 Participant Safety & Intent to Treat

As the HANDLS study cohort has aged, there are many participants who have developed new, more severe, or multiple chronic age-related medical conditions that require treatment. However, in this cohort participants are at times unable to regularly access needed care or are unable to be consistently compliant with medications and therapies. While participants are screened on the telephone and at times in person prior to setting their longitudinal visit appointments, participants usually do not fully relate their current medical status and level of compliance with prescribed medical regimens. Hence, we are at times confronted with participants in need of minor medical intervention. The frequency and severity of presenting symptomatology related to poorly controlled, chronic medical illness varies by participant and neighborhood demographics. Most often they report running low or out of medication because they cannot afford to fill the prescriptions to continue treatment. In those cases, once medically cleared, participants will be given a 2-4 week prescription and/or funds to fill the prescription.

Once symptoms are controlled, they will return for their study visit. In these cases, with participants consent, treatment provided will be shared with the primary care physician of record. If the participant does not have a physician and is agreeable, they will be provided the available resources and assistance to obtain a primary care physician and or health insurance, if necessary.

We have determined that at times, it may be necessary to temporarily suspend the research visit for ethical and safety reasons to administer initial urgent care for treatment of significant symptoms and physical examination findings before the participant can be discharged home, to their medical provider or the local emergency department. Circumstances can become quite complicated when participants exercise their right to refuse transport to an emergency department, HANDLS staff may not be able to contact the participant's primary care provider for an urgent appointment or the participant may not have a regular physician. There are five clinical presentations that we anticipate occurring episodically at the time of the HANDLS longitudinal visit and below we outline the proposed participant safety and well-being actions that will occur in keeping with standard medical practice and ethics:

17.1.1 Poorly controlled hypertension and related medical non-compliance

Some participants will have neglected to take their medications on the day of the exam despite being told the night before to take all anti-hypertensive medications and to bring all medications to the visit. This will result in an elevated screening blood pressure reading. Participants with values <200 systolic and <100 diastolic will be asked to take their medications immediately. Their blood pressure will be monitored for reduction upon which we will allow them to remain for the study visit. If there is no reduction in blood pressure, their visit will be terminated and they will be advised to take their mediation as directed and referred to their primary care physician for a blood pressure check for possible modification of their regimen. They will be recontacted in 30 days to again assess their suitability for reappointment.

Some participants will be newly diagnosed or non-compliant and have no anti-hypertensive medication. These participants will not continue their visit; they will be referred to their primary care physician for evaluation and treatment if they have a primary care physician. If there is no primary care practitioner, we will provide information about appropriate medical clinics in the vicinity in the context of their insurance status and ability to pay. Social work assistance is available on staff to assist medical staff in navigating the financial assessments. They will be recontacted in 30 days to again assess their suitability for reappointment.

Participants with SBP>200mmHg and/or a DBP >110mmHg will not continue with their visit and will be sent to the closest ER. If they decline, we will document their choice with an Against Medical Advice (AMA) note in the chart signed by the participant. However, in the interest of providing best available care, we will offer the alternate of administering Clonidine and providing a prescription for standard antihypertensive medications and an appointment for follow-up at the appropriate medical venue. They will be re-contacted in 30 days to again assess their suitability for reappointment.

17.1.2 Poorly controlled diabetes mellitus and related medical non-compliance

Some participants may present with symptoms of hyperglycemia due to medical or dietary noncompliance. If there are symptoms of hyperglycemia, a finger stick will be done. For participants with elevated glucose levels >400 but < 500 as determined by glucometer monitoring will be asked to take their medications if available. If they have been non-complaint with their medications or have no medications with them, they will be treated with sliding scale regular insulin and referred back to their primary care provider for evaluation after completing their longitudinal visit. If they have no medication at home, in the interest of providing the best care possible, we will provide a prescription for their previously prescribed hypoglycemic agent or an appropriate drug if they are unable to provide the name of the drug previously taken. They will be referred to an appropriate provider for disease management. Participants with glucose >500 will be referred to the ER and their testing suspended. If they refuse ER transport, we will document their choice with an Against Medical Advice (AMA) note in the chart signed by the participant. We will treat with regular insulin and attempt to get the soonest appointment with their provider or a provider at an appropriate medical clinic. These participants will be contacted 30 days after the interrupted testing to assess their suitability for completion of their longitudinal visit.

Some participants may mistakenly take their hypoglycemic agents while they are fasting in preparation for their visit and become hypoglycemic despite being instructed the night before the visit via telephone to bring their meds to take at the MRV after they have had their blood drawn and are ready for breakfast. Depending on their glucose level using finger stick glucometer monitoring we will administer glucotabs, oral juices or injectable glucagon. Testing will resume when patient is no longer hypoglycemic by finger stick glucometer monitoring.

17.1.3 Poorly controlled asthma/chronic obstructive pulmonary disease (COPD).

Participants at times are non-compliant with their medications or have run out of their prescriptions and present with or develop symptoms of wheezing or dyspnea. Participants with a pulse oximeter of 85-90% will receive albuterol nebulizer and/or oxygen as directed by the medical staff. If the subject's saturation does not return to 90% or greater after treatment and remains stable, the subject will be referred to the emergency room. Participants with pulse oximeter values <85% will be sent to the local emergency department. They will be re-contacted in 30 days to reassess their suitability for reappointment.

17.1.4 Alcohol Withdrawal

Participants who exhibit early signs and symptoms of alcohol withdrawal during testing, will have their testing interrupted and a detailed history taken of their alcohol use. Participants with prior history of severe alcohol withdrawal will be sent to the emergency room. In some instances, it may become necessary to give the participant an initial dose of short acting benzodiazepine to prevent further deterioration prior to the participant being transported to the nearest emergency room by the Emergency Medical System (EMS). Participants with no prior

history of severe alcohol withdrawal will be discharged home after receiving counseling and referral to an alcoholic detox program. Participants will be re-contacted in 30 days to reassess their suitability for reappointment.

17.1.5 Seizure Disorder

Participants with a known history of seizure disorder, who have a seizure while being testing, will have their testing for the day stopped. Depending upon the situation, EMS may be activated. Participants who have a singular seizure episode with full recovery will be discharged to their primary care provider. For participants who have repeated seizure episodes, EMS will be activated and the participant will be treated with short acting benzodiazepine prior to the EMS arrival. Participants will be re-contacted in 30 days to reassess their suitability for reappointment.

For all clinical presentations in sections 17.1.1 to 17.1.5 above:

Participants will be asked to sign an Against Medical Advice (AMA) note if they decline EMS and or transport to an emergency room or their primary care physician's office per study clinician's advice.

If a participant's study visit is terminated due to a medical problem identified on the MRV, the study team will attempt to re-contact participant within four days to follow up and determine the outcome of treatment recommendations.

17.2.0 Adverse Events and Unanticipated Problem Reporting

Adverse events associated with HANDLS study procedures are expected to occur very infrequently. Most of the potential risks associated with study procedures are limited to mild, transient discomforts of no clinical significance. Clinically significant adverse events, anticipated minor protocol deviations and anticipated problems or adverse events, as described in sections 17.0.0 - 17.1.5 above, will be reported to the IRB in compliance with NIH Policy 801, Reporting Research Events.

HANDLS staff is trained to detect and respond to clinically significant adverse events. They are expected to report clinically significant adverse events to the Principal Investigator immediately or as soon as is practical. The Principal Investigators for the HANDLS Scan and the Predictors of Personality (POP) sub-studies are also expected to report clinically significant adverse events immediately to the NIA Principal Investigators and to follow the adverse event reporting policies of their institutions.

All adverse events occurring during the study, including those observed by or reported to the research team, will be recorded. All reportable events will be reported to the IRB and NIA clinical director.

18.0.0 Site and Clinical Safety Monitoring Plan

The NIA Clinical Research Protocol Office will perform routine visits to the HANDLS research site to ensure the safety and conduct of the study complies with 45 CFR 46 and NIA guidelines. Audits are performed to assure that clinical research is in compliance with FDA, DHHS domestic regulations, Clinical Practice Guidelines (GCP), and local and federal human subjects standards. An audit may be performed following an adverse event, protocol deviation or at the time of annual renewal. The Clinical Protocol Coordinator of the Clinical Research Protocol Office determines the frequency of monitoring visits. Participant records are randomly selected from the protocol to be audited. Targeted audits may also be carried out when there is specific concern regarding patient safety or data integrity. The principal investigator and clinical research coordinator of the study are notified at least three weeks in advance of the audit, and are asked to supply all research records and patient medical records for the audit.

The NIA Clinical Research Protocol Office (CRPO) staff and the Clinical Protocol Coordinator of the Clinical Research Protocol Office (CRPO) carry out the audits. Audit format follows the NCI guidelines for national cooperative group audits. Following intensive review of the research and medical records, a formal written report of the audit findings is sent to the principal investigator and the NIA Clinical Director. The site visits will be recorded in a visit log, by the monitor, and kept at the HANDLS research site.

The monitor will review various aspects of the study including, but not limited to:

- (1) Compliance to the protocol;
- (2) Review of written informed consent forms for participants enrolled;
- (3) Comparison of clinic records (source documentation) to data recorded on case report forms to assure the completeness and accuracy of data collected;
- (4) Continued acceptability of facilities and staff; and,
- (5) Assessment of proper sample accountability, transfer and storage.

During the scheduled monitoring visits, source documentation will be made available to the monitor to substantiate proper informed consent procedures, adherence to protocol procedures, adequate reporting and follow-up of AEs. The Investigator (and as appropriate the research study staff) must be available to meet with the study monitor to discuss the findings from this review of Clinical Report Forms and source documents, make necessary corrections to case report form entries, respond to data clarification requests and respond to any other study-related inquiries of the monitor.

The principal investigator will be notified of any planned visit and a date will be set that is mutually agreeable. A report will be written to document all findings, solutions and discussions. The report or a follow-up letter summarizing the contents of the report will be sent to the principal investigator. Additional follow-up will be conducted by email and telephone as needed.

19.0.0 Research with Investigational Drugs or Devices

The HANDLS study is using 4 investigational drugs/devices to test for SARS-CoV-2 in study participants. The COVID tests listed below are not FDA-approved and are only for use under the Food and Drug Administration's Emergency Use Authorization.

Hologic Panther Fusion. The Panther FusionTM SARS-CoV-2 assay is a real-time RT-PCR in vitro diagnostic test intended for the detection of RNA from SARS-CoV-2 from nasopharyngeal (NP), nasal, oropharyngeal (OP) swab specimens and lower respiratory tract (LRT) specimens obtained from study participants who may have been exposed to COVID. The performance of this test was established based on the evaluation of a limited number of clinical specimens. The clinical performance has not been established in all circulating variants but is anticipated to be reflective of the prevalent variants in circulation at the time and location of the clinical evaluation. Risks to a patient of a false negative test result include delayed or lack of supportive treatment, lack of monitoring of infected individuals and their household or other close contacts for symptoms resulting in increased risk of spread of COVID-19 within the community, or other unintended adverse events.

This investigational device, as utilized in this study, is considered a Non-Significant Risk (NSR) device per 21 CFR 812.2(b)(1). The NSR classification was established as the device **does not meet** the following criteria for a Significant Risk Device (21 CFR 812(m)), i.e., a device that:

1. Is intended as an implant and presents a potential for serious risk to the health, safety, or welfare of a subject;

2. Is purported or represented to be for a use in supporting or sustaining human life and presents a potential for serious risk to the health, safety, or welfare of a subject;

3. Is for a use of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health and presents a potential for serious risk to the health, safety, or welfare of a subject; or

4. Otherwise presents a potential for serious risk to the health, safety or welfare of a subject.

Abbott Architect. The SARS-CoV-2 IgG assay is designed to detect immunoglobulin class G (IgG) antibodies to the nucleocapsid protein of SARS-CoV-2 in serum and plasma from individuals who are suspected to have had coronavirus disease (COVID-19) or in serum and plasma of subjects that may have been infected by SARS-CoV-2. The absolute sensitivity of the SARS-CoV-2 IgG assay is unknown. There is no known published information regarding adverse events.

This investigational device, as utilized in this study, is considered a Non-Significant Risk (NSR) device per 21 CFR 812.2(b)(1). The NSR classification was established as the device **does not meet** the following criteria for a Significant Risk Device (21 CFR 812(m)), i.e., a device that:

1. Is intended as an implant and presents a potential for serious risk to the health, safety, or welfare of a subject;

2. Is purported or represented to be for a use in supporting or sustaining human life and presents a potential for serious risk to the health, safety, or welfare of a subject;

3. Is for a use of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health and presents a potential for serious risk to the health, safety, or welfare of a subject; or

4. Otherwise presents a potential for serious risk to the health, safety or welfare of a subject.

BD Veritor. The BD Veritor TM System for Rapid Detection of SARSCoV-2 is authorized for use with direct anterior nasal swab specimens collected from individuals who are suspected of COVID-19 within the first five days of the onset of symptoms or from individuals without symptoms or other epidemiological reasons to suspect COVID-19, when tested twice over two or three days with at least 24 hours and no more than 48 hours between tests. The performance of this test was established based on the evaluation of a limited number of clinical specimens collected in the month of June 2020. The clinical performance has not been established in all circulating variants but is anticipated to be reflective of the prevalent variants in circulation at the time and location of the clinical evaluation. Performance at the time of testing may vary depending on the variants circulating, including newly emerging strains of SARS-CoV-2 and their prevalence, which change over time. Possible discomfort or other complications can happen during sample collection. No other specific information regarding adverse events is available or published.

This investigational device, as utilized in this study, is considered a Non-Significant Risk (NSR) device per 21 CFR 812.2(b)(1). The NSR classification was established as the device **does not meet** the following criteria for a Significant Risk Device (21 CFR 812(m)), i.e., a device that:

1. Is intended as an implant and presents a potential for serious risk to the health, safety, or welfare of a subject;

2. Is purported or represented to be for a use in supporting or sustaining human life and presents a potential for serious risk to the health, safety, or welfare of a subject;

3. Is for a use of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health and presents a potential for serious risk to the health, safety, or welfare of a subject; or

4. Otherwise presents a potential for serious risk to the health, safety or welfare of a subject.

Acon Laboratories, Inc. Flowflex COVID-19 Antigen Home Test. The Flowflex COVID-19 Antigen Home Test is authorized for non-prescription home or field use with self-collected anterior nasal swab specimens directly from individuals within 7 days of symptom onset or without symptoms or other epidemiological reasons to suspect COVID-19. This test is authorized for non-prescription use with self-collected anterior nasal samples from individuals 14 years or older or adult collected anterior nasal samples from individuals aged 2 years or older. The performance of this test was established based on the evaluation of a limited number of clinical specimens collected between March and May 2021. The clinical performance has not been established in all circulating variants but is anticipated to be reflective of the prevalent variants in circulation at the time and location of the clinical evaluation. Risks to an individual include possible discomfort during sample collection and possible incorrect test results resulting in delayed treatment, lack of monitoring of infected individuals and their household and close

contacts for symptoms resulting in increased spread of COVID-19 within the community or other unintended adverse events.

This investigational device, as utilized in this study, is considered a Non-Significant Risk (NSR) device per 21 CFR 812.2(b)(1). The NSR classification was established as the device **does not meet** the following criteria for a Significant Risk Device (21 CFR 812(m)), i.e., a device that:

1. Is intended as an implant and presents a potential for serious risk to the health, safety, or welfare of a subject;

2. Is purported or represented to be for a use in supporting or sustaining human life and presents a potential for serious risk to the health, safety, or welfare of a subject;

3. Is for a use of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health and presents a potential for serious risk to the health, safety, or welfare of a subject; or

4. Otherwise presents a potential for serious risk to the health, safety or welfare of a subject.

20.0.0 References

- 1. Ferraro KF, Farmer MM. Double jeopardy, aging as leveler, or persistent health inequality? A longitudinal analysis of white and black Americans. *J Gerontol B Psychol Sci Soc Sci.* 1996;51(6):S319-328.
- 2. Ferraro KF, Farmer MM, Wybraniec JA. Health trajectories: long-term dynamics among black and white adults. *J Health Soc Behav.* 1997;38(1):38-54.
- 3. Miles TP, Bernard MA. Morbidity, disability, and health status of black American elderly: a new look at the oldest-old [see comments]. *J Am Geriatr Soc.* 1992;40(10):1047-1054.
- 4. Smith JP, Kington R. Demographic and economic correlates of health in old age. *Demography.* 1997;34(1):159-170.
- 5. Zauszniewski JA, Wykle ML. Racial differences in self-assessed health problems, depressive cognitions, and learned resourcefulness. *J Natl Black Nurses Assoc.* 1994;7(1):3-14.
- Nicholas PK, Leuner JD. Hardiness, social support, and health status: are there differences in older African-American and Anglo-American adults? *Holist Nurs Pract*. 1999;13(3):53-61.
- 7. Johnson RJ, Wolinsky FD. Use of community-based long-term care services by older adults. *J Aging Health.* 1996;8(4):512-537.
- 8. Davis CM, Curley CM. Disparities of health in African Americans. *Nurs Clin North Am.* 1999;34(2):345-+.
- 9. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. *Diabetes Care.* 1999;22(3):403-408.
- 10. Cooper RS, Kaufman JS. Race and hypertension Science and nescience. *Hypertension*. 1998;32(5):813-816.
- 11. Ribisl KM, Winkleby MA, Fortmann SP, Flora JA. The interplay of socioeconomic status and ethnicity on Hispanic and White men's cardiovascular disease risk and health communication patterns. *Health Educ Res.* 1998;13(3):407-417.
- 12. Kim JS, Bramlett MH, Wright LK, Poon LW. Racial differences in health status and health behaviors of older adults. *Nurs Res.* 1998;47(4):243-250.
- 13. Fuortes LJ, Cowl CT, Reynolds SJ. Ethnic and socioeconomic risk factors for lead toxicity. *J Clean Technol Environ Toxicol Occup Med.* 1997;6(4):339-343.
- Sexton K. Sociodemographic aspects of human susceptibility to toxic chemicals: Do class and race matter for realistic risk assessment? *Environ Toxicol Pharmacol.* 1997;4(3-4):261-269.
- 15. Williams DR. Race and health: Basic questions, emerging directions. *Ann Epidemiol.* 1997;7(5):322-333.
- Kington RS, Smith JP. Socioeconomic status and racial and ethnic differences in functional status associated with chronic diseases. *Am J Public Health.* 1997;87(5):805-810.
- 17. Kochanek KD, Maurer JD, Rosenberg HM. Why did black life expectancy decline from 1984 through 1989 in the United States? [see comments]. *Am J Public Health*. 1994;84(6):938-944.

- 18. Jackson JS, Brown TN, Williams DR, Torres M, Sellers SL, Brown K. Racism and the physical and mental health status of African Americans: a thirteen year national panel study. *Ethn Dis.* 1996;6(1-2):132-147.
- 19. Ng-Mak DS, Dohrenwend BP, Abraido-Lanza AF, Turner JB. A further analysis of race differences in the National Longitudinal Mortality Study. *Am J Public Health*. 1999;89(11):1748-1751.
- 20. LillieBlanton M, Parsons PE, Gayle H, Dievler A. Racial differences in health: Not just black and white, but shades of gray. *Annual Review of Public Health.* 1996;17:411-448.
- 21. Williams DR, Collins C. US Socioeconomic and Racial-Differences in Health Patterns and Explanations. *Annu Rev Sociol.* 1995;21:349-386.
- 22. Olshansky SJ, Antonucci T, Berkman L, et al. Differences in life expectancy due to race and educational differences are widening, and many may not catch up. *Health affairs*. 2012;31(8):1803-1813.
- 23. Ferraro KF, Farmer MM. Double jeopardy to health hypothesis for African Americans: analysis and critique. *J Health Soc Behav.* 1996;37(1):27-43.
- 24. Schulman KA, Berlin JA, Harless W, et al. The effect of race and sex on physicians' recommendations for cardiac catheterization [see comments] [published erratum appears in N Engl J Med 1999 Apr 8;340(14):1130]. *N Engl J Med*. 1999;340(8):618-626.
- 25. Dressel P, Minkler M, Yen I. Gender, race, class, and aging: advances and opportunities. *Int J Health Serv.* 1997;27(4):579-600.
- 26. Roetzheim RG, Pal N, Tennant C, et al. Effects of health insurance and race on early detection of cancer. *J Natl Cancer Inst.* 1999;91(16):1409-1415.
- 27. Williams DR. Race/ethnicity and socioeconomic status: Measurement and methodological issues. *Int J Health Serv.* 1996;26(3):483-505.
- 28. Case A, Deaton A. Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century. *Proc Natl Acad Sci U S A.* 2015;112(49):15078-15083.
- 29. Sanderson BK, Raczynski JM, Cornell CE, Hardin M, Taylor HA. Ethnic disparities in patient recall of physician recommendations of diagnostic and treatment procedures for coronary disease. *Am J Epidemiol.* 1998;148(8):741-749.
- 30. Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. *Genome Med.* 2016;8(1):51.
- 31. Grice EA, Segre JA. The skin microbiome. *Nat Rev Microbiol.* 2011;9(4):244-253.
- 32. Sanford JA, Gallo RL. Functions of the skin microbiota in health and disease. *Semin Immunol.* 2013;25(5):370-377.
- Weyrich LS, Dixit S, Farrer AG, Cooper AJ, Cooper AJ. The skin microbiome: Associations between altered microbial communities and disease. *Australas J Dermatol.* 2015;56(4):268-274.
- Wong VW, Martindale RG, Longaker MT, Gurtner GC. From germ theory to germ therapy: skin microbiota, chronic wounds, and probiotics. *Plast Reconstr Surg.* 2013;132(5):854e-861e.
- 35. Heintz C, Mair W. You are what you host: microbiome modulation of the aging process. *Cell.* 2014;156(3):408-411.
- 36. Egert M, Simmering R. The Microbiota of the Human Skin. *Adv Exp Med Biol.* 2016;902:61-81.

- 37. Grice EA, Kong HH, Renaud G, et al. A diversity profile of the human skin microbiota. *Genome Res.* 2008;18(7):1043-1050.
- 38. Collins AR. Molecular epidemiology in cancer research. *Molecular aspects of medicine*. 1998;19(6):359-432.
- 39. Hannon-Fletcher MP, O'Kane MJ, Moles KW, Weatherup C, Barnett CR, Barnett YA. Levels of peripheral blood cell DNA damage in insulin dependent diabetes mellitus human subjects. *Mutation research.* 2000;460(1):53-60.
- 40. Malins DC, Johnson PM, Wheeler TM, Barker EA, Polissar NL, Vinson MA. Age-related radical-induced DNA damage is linked to prostate cancer. *Cancer Res.* 2001;61(16):6025-6028.
- 41. Morocz M, Kalman J, Juhasz A, et al. Elevated levels of oxidative DNA damage in lymphocytes from patients with Alzheimer's disease. *Neurobiol Aging.* 2002;23(1):47-53.
- 42. Domenici FA, Vannucchi MT, Jordao AA, Jr., Meirelles MS, Vannucchi H. DNA oxidative damage in patients with dialysis treatment. *Renal failure*. 2005;27(6):689-694.
- 43. Trzeciak A, Kowalik J, Malecka-Panas E, et al. Genotoxicity of chromium in human gastric mucosa cells and peripheral blood lymphocytes evaluated by the single cell gel electrophoresis (comet assay). *Med Sci Monit.* 2000;6(1):24-29.
- 44. Piperakis SM, Visvardis EE, Sagnou M, Tassiou AM. Effects of smoking and aging on oxidative DNA damage of human lymphocytes. *Carcinogenesis*. 1998;19(4):695-698.
- 45. Knaapen AM, Schins RP, Polat D, Becker A, Borm PJ. Mechanisms of neutrophil-induced DNA damage in respiratory tract epithelial cells. *Mol Cell Biochem.* 2002;234-235(1-2):143-151.
- 46. Olden K, White SL. Health-related disparities: influence of environmental factors. *Med Clin North Am.* 2005;89(4):721-738.
- 47. Said S, Hernandez GT. Environmental exposures, socioeconomics, disparities, and the kidneys. *Adv Chronic Kidney Dis.* 2015;22(1):39-45.
- 48. Grashow R, Sparrow D, Hu H, Weisskopf MG. Cumulative lead exposure is associated with reduced olfactory recognition performance in elderly men: The Normative Aging Study. *Neurotoxicology.* 2015;49:158-164.
- 49. Farooqui Z, Bakulski KM, Power MC, et al. Associations of cumulative Pb exposure and longitudinal changes in Mini-Mental Status Exam scores, global cognition and domains of cognition: The VA Normative Aging Study. *Environ Res.* 2017;152:102-108.
- 50. Foster M, Samman S. Zinc and redox signaling: perturbations associated with cardiovascular disease and diabetes mellitus. *Antioxid Redox Signal.* 2010;13(10):1549-1573.
- 51. Park JS, Xun P, Li J, et al. Longitudinal association between toenail zinc levels and the incidence of diabetes among American young adults: The CARDIA Trace Element Study. *Sci Rep.* 2016;6:23155.
- 52. Rayman MP. Selenium and human health. *Lancet.* 2012;379(9822):1256-1268.
- 53. Abdul KS, Jayasinghe SS, Chandana EP, Jayasumana C, De Silva PM. Arsenic and human health effects: A review. *Environ Toxicol Pharmacol.* 2015;40(3):828-846.
- 54. Sidhu MS, Desai KP, Lynch HN, Rhomberg LR, Beck BD, Venditti FJ. Mechanisms of action for arsenic in cardiovascular toxicity and implications for risk assessment. *Toxicology*. 2015;331:78-99.

- 55. Slotnick MJ, Meliker JR, Nriagu JO. Intra-individual variability in toenail arsenic concentrations in a Michigan population, USA. *J Expo Sci Environ Epidemiol.* 2008;18(2):149-157.
- 56. Freedberg I.M. EAZ, Wolf K., et al. *Fitzpatrick's Dermatology in General Medicine*. New York: McGraw Hill; 1999.
- 57. Ab Razak NH, Praveena SM, Hashim Z. Toenail as a biomarker of heavy metal exposure via drinking water: a systematic review. *Rev Environ Health.* 2015;30(1):1-7.
- 58. Barbosa F, Jr., Tanus-Santos JE, Gerlach RF, Parsons PJ. A critical review of biomarkers used for monitoring human exposure to lead: advantages, limitations, and future needs. *Environ Health Perspect*. 2005;113(12):1669-1674.
- 59. Esteban M, Castano A. Non-invasive matrices in human biomonitoring: a review. *Environ Int.* 2009;35(2):438-449.
- 60. Garland M, Morris JS, Colditz GA, et al. Toenail trace element levels and breast cancer: a prospective study. *Am J Epidemiol*. 1996;144(7):653-660.
- 61. Garland M, Morris JS, Rosner BA, et al. Toenail trace element levels as biomarkers: reproducibility over a 6-year period. *Cancer Epidemiol Biomarkers Prev.* 1993;2(5):493-497.
- 62. US Renal Data System. USRDS 2007 annual data report: atlas of end-stage renal disease in the United States. In: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease. Bethesda, MD; 2007.
- 63. Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. *J Am Soc Nephrol.* 2003;14(11):2934-2941.
- 64. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. End-stage renal disease in African-American and white men. 16-year MRFIT findings. *Jama*. 1997;277(16):1293-1298.
- 65. Volkova N, McClellan W, Klein M, et al. Neighborhood poverty and racial differences in ESRD incidence. *J Am Soc Nephrol.* 2008;19(2):356-364.
- 66. Ward MM. Access to care and the incidence of end-stage renal disease due to diabetes. *Diabetes Care.* 2009;32(6):1032-1036.
- 67. Plantinga LC, Johansen K, Crews DC, et al. Association of CKD with disability in the United States. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2011;57(2):212-227.
- 68. Plantinga LC, Crews DC, Coresh J, et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. *Clinical journal of the American Society of Nephrology : CJASN*. 2010;5(4):673-682.
- 69. Nickolas TL, Barasch J, Devarajan P. Biomarkers in acute and chronic kidney disease. *Current opinion in nephrology and hypertension.* 2008;17(2):127-132.
- 70. Plassman BL, Langa KM, Fisher GG, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. *Neuroepidemiology*. 2007;29(1-2):125-132.
- 71. Mayeda ER, Glymour MM, Quesenberry CP, Whitmer RA. Inequalities in dementia incidence between six racial and ethnic groups over 14 years. *Alzheimers Dement*. 2016;12(3):216-224.

- 72. Yaffe K, Falvey C, Harris TB, et al. Effect of socioeconomic disparities on incidence of dementia among biracial older adults: prospective study. *BMJ.* 2013;347:f7051.
- 73. Alzheimer's Association. Alzheimer's and public health spotlight: Race, ethnicity & Alzheimer's disease. <u>https://www.alz.org/documents_custom/public-health/spotlight-race-ethnicity.pdf</u>. Published 2016. Updated 8 December 2016. Accessed.
- 74. Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R. Influence of education and occupation on the incidence of Alzheimer's disease. *JAMA*. 1994;271(13):1004-1010.
- 75. U.S. Department of Health and Human Services. National plan to address Alzheimer's disease: 2016 update. <u>https://aspe.hhs.gov/report/national-plan-address-alzheimers-disease-2016-update</u>. Published 2016. Updated 8 December 2016. Accessed.
- Quarmley M, Moberg PJ, Mechanic-Hamilton D, et al. Odor Identification Screening Improves Diagnostic Classification in Incipient Alzheimer's Disease. J Alzheimers Dis. 2017;55(4):1497-1507.
- 77. Sohrabi HR, Bates KA, Weinborn MG, et al. Olfactory discrimination predicts cognitive decline among community-dwelling older adults. *Transl Psychiatry.* 2012;2:e118.
- 78. Qiu M, Wang SY, Singh K, Lin SC. Racial disparities in uncorrected and undercorrected refractive error in the United States. *Invest Ophthalmol Vis Sci.* 2014;55(10):6996-7005.
- 79. National Academies of Sciences Engineering and Medicine. *Making eye health a population health imperative : vision for tomorrow.* Washington, DC: National Academies Press; 2016.
- 80. Howard DH, Sentell T, Gazmararian JA. Impact of health literacy on socioeconomic and racial differences in health in an elderly population. *Journal of general internal medicine*. 2006;21(8):857-861.
- 81. Paasche-Orlow MK, Parker RM, Gazmararian JA, Nielsen-Bohlman LT, Rudd RR. The prevalence of limited health literacy. *Journal of general internal medicine*. 2005;20(2):175-184.
- 82. Fraser SD, Roderick PJ, Casey M, Taal MW, Yuen HM, Nutbeam D. Prevalence and associations of limited health literacy in chronic kidney disease: a systematic review. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association European Renal Association.* 2013;28(1):129-137.
- 83. Sahm LJ, Wolf MS, Curtis LM, McCarthy S. Prevalence of limited health literacy among Irish adults. *Journal of health communication.* 2012;17 Suppl 3:100-108.
- Morris NS, Grant S, Repp A, Maclean C, Littenberg B. Prevalence of limited health literacy and compensatory strategies used by hospitalized patients. *Nurs Res.* 2011;60(5):361-366.
- 85. Davis TC, Crouch MA, Long SW, et al. Rapid assessment of literacy levels of adult primary care patients. *Family medicine*. 1991;23(6):433-435.
- 86. Paasche-Orlow MK, Wolf MS. Promoting health literacy research to reduce health disparities. *Journal of health communication*. 2010;15 Suppl 2:34-41.
- 87. Sudore RL, Yaffe K, Satterfield S, et al. Limited literacy and mortality in the elderly: the health, aging, and body composition study. *Journal of general internal medicine*. 2006;21(8):806-812.

- 88. Sudore RL, Mehta KM, Simonsick EM, et al. Limited literacy in older people and disparities in health and healthcare access. *J Am Geriatr Soc.* 2006;54(5):770-776.
- 89. Parker RM, Baker DW, Williams MV, Nurss JR. The test of functional health literacy in adults: a new instrument for measuring patients' literacy skills. *Journal of general internal medicine*. 1995;10(10):537-541.
- 90. Evans MK, Lepkowski JM, Powe NR, LaVeist T, Kuczmarski MF, Zonderman AB. Healthy aging in neighborhoods of diversity across the life span (HANDLS): overcoming barriers to implementing a longitudinal, epidemiologic, urban study of health, race, and socioeconomic status. *Ethn Dis.* 2010;20(3):267-275.
- 91. Sood N, Simon P, Ebner P, et al. Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Los Angeles County, California, on April 10-11, 2020. *JAMA*. 2020.
- 92. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. *Science*. 2020;368(6493):860-868.
- 93. Ahmadpoor P, Rostaing L. Why the immune system fails to mount an adaptive immune response to a COVID-19 infection. *Transpl Int.* 2020;33(7):824-825.
- 94. Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. *Cell Death Differ.* 2020;27(5):1451-1454.
- 95. Weltevrede M, Eilers R, de Melker HE, van Baarle D. Cytomegalovirus persistence and Tcell immunosenescence in people aged fifty and older: A systematic review. *Exp Gerontol.* 2016;77:87-95.
- 96. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive Care Med.* 2020;46(4):586-590.
- 97. Cao Y, Li L, Feng Z, et al. Comparative genetic analysis of the novel coronavirus (2019nCoV/SARS-CoV-2) receptor ACE2 in different populations. *Cell Discov.* 2020;6:11.
- 98. Zhao Y, Zhao, Z., Wang, Y., Zhou, Y., Ma, Y., Zuo, W. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. *bioRxiv*. 2020.
- 99. Gorelick PB. Cerebrovascular disease in African Americans. *Stroke.* 1998;29(12):2656-2664.
- Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. *N Engl J Med.* 2003;348(13):1215-1222.
- 101. Morgenstern LB, Spears WD, Goff DC, Jr., Grotta JC, Nichaman MZ. African Americans and women have the highest stroke mortality in Texas. *Stroke.* 1997;28(1):15-18.
- 102. Holtmannspotter M, Peters N, Opherk C, et al. Diffusion magnetic resonance histograms as a surrogate marker and predictor of disease progression in CADASIL: A two-year follow-up study. *Stroke*. 2005;36(12):2559-2565.
- 103. Smith EE, Egorova S, Blacker D, et al. Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. *Arch Neurol.* 2008;65(1):94-100.
- 104. Adler NE, Rehkopf DH. U.S. disparities in health: descriptions, causes, and mechanisms. *Annu Rev Public Health.* 2008;29:235-252.

- 105. Gallo LC, Matthews KA. Understanding the association between socioeconomic status and physical health: Do negative emotions play a role? *Psychol Bull.* 2003;129(1):10-51.
- 106. Cox AM, McKevitt C, Rudd AG, Wolfe CD. Socioeconomic status and stroke. *Lancet Neurol.* 2006;5(2):181-188.
- Brickman AM, Schupf N, Manly JJ, et al. Brain morphology in older African Americans, Caribbean Hispanics, and whites from northern Manhattan. *Arch Neurol.* 2008;65(8):1053-1061.
- 108. Minati L, Grisoli M, Bruzzone MG. MR spectroscopy, functional MRI, and diffusiontensor imaging in the aging brain: A conceptual review. *J Geriatr Psychiatry Neurol*. 2007;20(1):3-21.
- 109. Grieve SM, Williams LM, Paul RH, Clark CR, Gordon E. Cognitive aging, executive function, and fractional anisotropy: a diffusion tensor MR imaging study. *AJNR Am J Neuroradiol*. 2007;28(2):226-235.
- 110. Roberts BW, Kuncel NR, Shiner R, Caspi A, Goldberg LR. The Power of Personality: The Comparative Validity of Personality Traits, Socioeconomic Status, and Cognitive Ability for Predicting Important Life Outcomes. *Perspect Psychol Sci.* 2007;2(4):313-345.
- 111. Kern ML, Friedman HS. Do conscientious individuals live longer? A quantitative review. *Health Psychol.* 2008;27(5):505-512.
- 112. Terracciano A, Lockenhoff CE, Zonderman AB, Ferrucci L, Costa PT, Jr. Personality predictors of longevity: activity, emotional stability, and conscientiousness. *Psychosom Med.* 2008;70(6):621-627.
- 113. Terracciano A, Strait J, Scuteri A, et al. Personality traits and circadian blood pressure patterns: a 7-year prospective study. *Psychosom Med.* 2014;76(3):237-243.
- 114. Jokela M, Elovainio M, Nyberg ST, et al. Personality and risk of diabetes in adults: pooled analysis of 5 cohort studies. *Health Psychol.* 2014;33(12):1618-1621.
- 115. Sutin AR, Costa PT, Jr., Uda M, Ferrucci L, Schlessinger D, Terracciano A. Personality and metabolic syndrome. *Age (Dordr)*. 2010;32(4):513-519.
- 116. Sutin AR, Terracciano A, Deiana B, et al. High neuroticism and low conscientiousness are associated with interleukin-6. *Psychol Med.* 2010;40(9):1485-1493.
- 117. Mottus R, Luciano M, Starr JM, Pollard MC, Deary IJ. Personality traits and inflammation in men and women in their early 70s: the Lothian Birth Cohort 1936 study of healthy aging. *Psychosom Med.* 2013;75(1):11-19.
- 118. Terracciano A, Schrack JA, Sutin AR, Chan W, Simonsick EM, Ferrucci L. Personality, metabolic rate and aerobic capacity. *PLoS One.* 2013;8(1):e54746.
- 119. Kendler KS, Myers J. The genetic and environmental relationship between major depression and the five-factor model of personality. *Psychol Med.* 2010;40(5):801-806.
- 120. Wilson RS, Schneider JA, Arnold SE, Bienias JL, Bennett DA. Conscientiousness and the incidence of Alzheimer disease and mild cognitive impairment. *Arch Gen Psychiatry*. 2007;64(10):1204-1212.
- 121. Terracciano A, Sutin AR, An Y, et al. Personality and risk of Alzheimer's disease: new data and meta-analysis. *Alzheimers Dement.* 2014;10(2):179-186.
- 122. Weiss A, Sutin AR, Duberstein PR, Friedman B, Bagby RM, Costa PT, Jr. The personality domains and styles of the five-factor model are related to incident depression in Medicare recipients aged 65 to 100. *Am J Geriatr Psychiatry*. 2009;17(7):591-601.

- 123. Lee HB, Offidani E, Ziegelstein RC, et al. Five-factor model personality traits as predictors of incident coronary heart disease in the community: a 10.5-year cohort study based on the Baltimore epidemiologic catchment area follow-up study. *Psychosomatics*. 2014;55(4):352-361.
- 124. Goodwin RD, Friedman HS. Health status and the five-factor personality traits in a nationally representative sample. *J Health Psychol.* 2006;11(5):643-654.
- 125. Wilson RS, Arnold SE, Schneider JA, Kelly JF, Tang Y, Bennett DA. Chronic psychological distress and risk of Alzheimer's disease in old age. *Neuroepidemiology.* 2006;27(3):143-153.
- 126. Chapman BP, Hampson S, Clarkin J. Personality-informed interventions for healthy aging: conclusions from a National Institute on Aging work group. *Dev Psychol.* 2014;50(5):1426-1441.
- 127. U.S. Department of Health and Human Services. *Healthy People 2010: Understanding and Improving Public Health.* Washington DC: U.S. Department of Health and Human Services;2000.
- 128. Goldman N. Social inequalities in health disentangling the underlying mechanisms. *Ann N Y Acad Sci.* 2001;954:118-139.
- 129. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res.* 1975;12(3):189-198.
- 130. Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. *Applied Psychological Measurement*. 1977;1(3):385-401.
- 131. Guralnik JM, Winograd CH. Physical performance measures in the assessment of older persons. *Aging.* 1994;6(5):303-305.
- 132. Simonsick EM, Kasper JD, Guralnik JM, et al. Severity of upper and lower extremity functional limitation: scale development and validation with self-report and performance-based measures of physical function. WHAS Research Group. Women's Health and Aging Study. *J Gerontol B Psychol Sci Soc Sci.* 2001;56(1):S10-19.
- 133. Burke GL, Evans GW, Riley WA, et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. *Stroke.* 1995;26(3):386-391.
- Chambless LE, Folsom AR, Clegg LX, et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. *Am J Epidemiol.* 2000;151(5):478-487.
- 135. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK, Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. *N Engl J Med.* 1999;340(1):14-22.
- Nagai Y, Metter EJ, Earley CJ, et al. Increased carotid artery intimal-medial thickness in asymptomatic older subjects with exercise-induced myocardial ischemia. *Circulation*. 1998;98(15):1504-1509.
- 137. Mulukutla SR, Venkitachalam L, Bambs C, et al. Black race is associated with digital artery endothelial dysfunction: results from the Heart SCORE study. *European heart journal.* 2010;31(22):2808-2815.

- 138. Patel PD, Velazquez JL, Arora RR. Endothelial dysfunction in African-Americans. *International journal of cardiology*. 2009;132(2):157-172.
- 139. Rubinshtein R, Kuvin JT, Soffler M, et al. Assessment of endothelial function by noninvasive peripheral arterial tonometry predicts late cardiovascular adverse events. *European heart journal.* 2010;31(9):1142-1148.
- 140. Patvardhan EA, Heffernan KS, Ruan JM, Soffler MI, Karas RH, Kuvin JT. Assessment of vascular endothelial function with peripheral arterial tonometry: information at your fingertips? *Cardiology in review*. 2010;18(1):20-28.
- 141. Morris AA, Patel RS, Binongo JN, et al. Racial differences in arterial stiffness and microcirculatory function between Black and White Americans. *Journal of the American Heart Association*. 2013;2(2):e002154.
- 142. Aboyans V, Criqui MH, Abraham P, et al. Measurement and interpretation of the anklebrachial index: a scientific statement from the American Heart Association. *Circulation*. 2012;126(24):2890-2909.
- 143. Kim ES, Wattanakit K, Gornik HL. Using the ankle-brachial index to diagnose peripheral artery disease and assess cardiovascular risk. *Cleveland Clinic journal of medicine*. 2012;79(9):651-661.